

Madhukar Trivedi

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3823988/madhukar-trivedi-publications-by-citations.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

662 papers	44,856 citations	99 h-index	194 g-index
718 ext. papers	52,202 ext. citations	5.7 avg, IF	7.16 L-index

#	Paper	IF	Citations
662	Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. <i>American Journal of Psychiatry</i> , 2006 , 163, 1905-17	11.9	3098
661	Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. <i>American Journal of Psychiatry</i> , 2006 , 163, 28-40	11.9	2607
660	The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. <i>Biological Psychiatry</i> , 2003 , 54, 573-83	7.9	2278
659	The Inventory of Depressive Symptomatology (IDS): psychometric properties. <i>Psychological Medicine</i> , 1996 , 26, 477-86	6.9	1465
658	A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. <i>New England Journal of Medicine</i> , 2000 , 342, 1462-70	59.2	985
657	Exercise treatment for depression: efficacy and dose response. <i>American Journal of Preventive Medicine</i> , 2005 , 28, 1-8	6.1	824
656	Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. <i>New England Journal of Medicine</i> , 2006 , 354, 1231-42	59.2	778
655	Medication augmentation after the failure of SSRIs for depression. <i>New England Journal of Medicine</i> , 2006 , 354, 1243-52	59.2	748
654	Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. <i>Contemporary Clinical Trials</i> , 2004 , 25, 119-42		725
653	The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. <i>Psychological Medicine</i> , 2004 , 34, 73-82	6.9	654
652	Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. <i>American Journal of Psychiatry</i> , 2008 , 165, 342-51	11.9	594
651	Physical activity dose-response effects on outcomes of depression and anxiety. <i>Medicine and Science in Sports and Exercise</i> , 2001 , 33, S587-97; discussion 609-10	1.2	472
650	Report by the ACNP Task Force on response and remission in major depressive disorder. <i>Neuropsychopharmacology</i> , 2006 , 31, 1841-53	8.7	469
649	The STAR*D Project results: a comprehensive review of findings. <i>Current Psychiatry Reports</i> , 2007 , 9, 449-59	9.1	443
648	Remissions in maternal depression and child psychopathology: a STAR*D-child report. <i>JAMA - Journal of the American Medical Association</i> , 2006 , 295, 1389-98	27.4	442
647	Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. <i>American Journal of Human Genetics</i> , 2006 , 78, 804-814	11	396
646	A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. <i>American Journal of Psychiatry</i> , 2006 , 163, 1519-30; quiz 1665	11.9	380

645	Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. <i>Psychiatric Clinics of North America</i> , 2003 , 26, 457-94, x	3.1	373
644	What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. <i>Psychiatric Services</i> , 2009 , 60, 1439-45	3.3	368
643	The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. <i>Journal of Clinical Psychopharmacology</i> , 2008 , 28, 156-65	1.7	335
642	Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , 2002 , 287, 1807-14	27.4	311
641	Cross-trial prediction of treatment outcome in depression: a machine learning approach. <i>Lancet Psychiatry</i> , 2016 , 3, 243-50	23.3	310
640	The pattern of sensory processing abnormalities in autism. <i>Autism</i> , 2006 , 10, 480-94	6.6	302
639	An evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report. <i>Biological Psychiatry</i> , 2006 , 59, 493-501	7.9	300
638	Effect of age at onset on the course of major depressive disorder. <i>American Journal of Psychiatry</i> , 2007 , 164, 1539-46	11.9	295
637	Gender differences in depression: findings from the STAR*D study. <i>Journal of Affective Disorders</i> , 2005 , 87, 141-50	6.6	292
636	Harmonization of cortical thickness measurements across scanners and sites. <i>NeuroImage</i> , 2018 , 167, 104-120	7.9	286
635	Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. <i>Psychological Medicine</i> , 2010 , 40, 41-50	6.9	283
634	Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. <i>American Journal of Psychiatry</i> , 2019 , 176, 428-438	11.9	282
633	Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. <i>American Journal of Psychiatry</i> , 2011 , 168, 689-701	11.9	266
632	Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D. <i>Psychological Medicine</i> , 2004 , 34, 1299-308	6.9	261
631	Inverse association between physical inactivity and mental health in men and women. <i>Medicine and Science in Sports and Exercise</i> , 2006 , 38, 173-8	1.2	247
630	Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. <i>American Journal of Psychiatry</i> , 2007 , 164, 739-52	11.9	246
629	Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. <i>American Journal of Psychiatry</i> , 2006 , 163, 1531-41; quiz 1666	11.9	244
628	Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. <i>JAMA Psychiatry</i> , 2019 , 76, 893-903	14.5	238

627	Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. <i>Archives of General Psychiatry</i> , 2004 , 61, 669-80		225
626	Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. <i>CNS Spectrums</i> , 2009 , 14, 197-206	1.8	207
625	Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1). <i>International Journal of Neuropsychopharmacology</i> , 2019 , 22, 616-630	5.8	205
624	A Comparison of Mirtazapine and Nortriptyline Following Two Consecutive Failed Medication Treatments for Depressed Outpatients: A STAR*D Report. <i>American Journal of Psychiatry</i> , 2006 , 163, 1161-1172	11.9	203
623	Comorbid psychiatric disorders in depressed outpatients: demographic and clinical features. <i>Journal of Affective Disorders</i> , 2005 , 87, 43-55	6.6	185
622	Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. <i>Archives of General Psychiatry</i> , 2007 , 64, 783-92		182
621	Cognitive dysfunction in unipolar depression: implications for treatment. <i>Journal of Affective Disorders</i> , 2014 , 152-154, 19-27	6.6	179
620	Self-rated global measure of the frequency, intensity, and burden of side effects. <i>Journal of Psychiatric Practice</i> , 2006 , 12, 71-9	1.3	176
619	Psychotherapy and medication in the treatment of adult and geriatric depression: which monotherapy or combined treatment?. <i>Journal of Clinical Psychiatry</i> , 2005 , 66, 455-68	4.6	176
618	STAR*D: revising conventional wisdom. <i>CNS Drugs</i> , 2009 , 23, 627-47	6.7	172
617	Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination. <i>Biological Psychiatry</i> , 2002 , 51, 123-33	7.9	172
616	Identifying predictors, moderators, and mediators of antidepressant response in major depressive disorder: neuroimaging approaches. <i>American Journal of Psychiatry</i> , 2015 , 172, 124-38	11.9	171
615	Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report. <i>American Journal of Psychiatry</i> , 2009 , 166, 599-607	11.9	171
614	Sensory correlations in autism. <i>Autism</i> , 2007 , 11, 123-34	6.6	162
613	The Texas Medication Algorithm Project. <i>Journal of Clinical Psychiatry</i> , 1999 , 60, 142-156	4.6	160
612	Sex differences in depression symptoms in treatment-seeking adults: confirmatory analyses from the Sequenced Treatment Alternatives to Relieve Depression study. <i>Comprehensive Psychiatry</i> , 2008 , 49, 238-46	7.3	156
611	Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): Rationale and design. <i>Journal of Psychiatric Research</i> , 2016 , 78, 11-23	5.2	153
610	The Montgomery Asberg and the Hamilton ratings of depression: a comparison of measures. <i>European Neuropsychopharmacology</i> , 2006 , 16, 601-11	1.2	150

609	Does a placebo run-in or a placebo treatment cell affect the efficacy of antidepressant medications?. <i>Neuropsychopharmacology</i> , 1994 , 11, 33-43	8.7	150
608	MAOIs in the contemporary treatment of depression. <i>Neuropsychopharmacology</i> , 1995 , 12, 185-219	8.7	149
607	Children of depressed mothers 1 year after the initiation of maternal treatment: findings from the STAR*D-Child Study. <i>American Journal of Psychiatry</i> , 2008 , 165, 1136-47	11.9	146
606	Exercise as an augmentation treatment for nonremitted major depressive disorder: a randomized, parallel dose comparison. <i>Journal of Clinical Psychiatry</i> , 2011 , 72, 677-84	4.6	146
605	Cognitive behavioral analysis system of psychotherapy and brief supportive psychotherapy for augmentation of antidepressant nonresponse in chronic depression: the REVAMP Trial. <i>Archives of General Psychiatry</i> , 2009 , 66, 1178-88		145
604	Association between major depressive episodes in patients with chronic kidney disease and initiation of dialysis, hospitalization, or death. <i>JAMA - Journal of the American Medical Association</i> , 2010 , 303, 1946-53	27.4	143
603	Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial. <i>Journal of Clinical Psychiatry</i> , 2010 , 71, 616-26	4.6	142
602	Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in Major Depressive Disorder: results of the BRITE-MD study. <i>Psychiatry Research</i> , 2009 , 169, 124-31	9.9	140
601	Pro-inflammatory cytokines as predictors of antidepressant effects of exercise in major depressive disorder. <i>Molecular Psychiatry</i> , 2013 , 18, 1119-24	15.1	137
600	Factors associated with chronic depressive episodes: a preliminary report from the STAR-D project. <i>Acta Psychiatrica Scandinavica</i> , 2005 , 112, 425-33	6.5	137
599	Reevaluating the Efficacy and Predictability of Antidepressant Treatments: A Symptom Clustering Approach. <i>JAMA Psychiatry</i> , 2017 , 74, 370-378	14.5	135
598	Defining and measuring functional recovery from depression. <i>CNS Drugs</i> , 2010 , 24, 267-84	6.7	128
597	Dream recall and major depression: A preliminary report.. <i>Dreaming</i> , 1995 , 5, 189-198	6	127
596	Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. <i>Archives of General Psychiatry</i> , 2008 , 65, 870-80		125
595	Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). <i>Molecular Psychiatry</i> , 2020 , 25, 1592-1603	15.1	125
594	Children of depressed mothers 1 year after remission of maternal depression: findings from the STAR*D-Child study. <i>American Journal of Psychiatry</i> , 2011 , 168, 593-602	11.9	124
593	Strengthening clinical effectiveness trials: equipoise-stratified randomization. <i>Biological Psychiatry</i> , 2001 , 50, 792-801	7.9	124
592	Opioid Modulation With Buprenorphine/Samidorphan as Adjunctive Treatment for Inadequate Response to Antidepressants: A Randomized Double-Blind Placebo-Controlled Trial. <i>American Journal of Psychiatry</i> , 2016 , 173, 499-508	11.9	123

591	Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. <i>Journal of Clinical Psychopharmacology</i> , 2011 , 31, 180-6	1.7	123
590	Sex differences in response to citalopram: a STAR*D report. <i>Journal of Psychiatric Research</i> , 2009 , 43, 503-11	5.2	123
589	Exercise as an augmentation strategy for treatment of major depression. <i>Journal of Psychiatric Practice</i> , 2006 , 12, 205-13	1.3	120
588	Texas Children's Medication Algorithm Project: update from Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2007 , 46, 667-686	7.2	119
587	Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial. <i>Psychoneuroendocrinology</i> , 2017 , 78, 105-113	5	118
586	The STAR*D study: treating depression in the real world. <i>Cleveland Clinic Journal of Medicine</i> , 2008 , 75, 57-66	2.8	117
585	Statistical harmonization corrects site effects in functional connectivity measurements from multi-site fMRI data. <i>Human Brain Mapping</i> , 2018 , 39, 4213-4227	5.9	117
584	What clinical and symptom features and comorbid disorders characterize outpatients with anxious major depressive disorder: a replication and extension. <i>Canadian Journal of Psychiatry</i> , 2006 , 51, 823-35	4.8	115
583	Slow-wave activity in NREM sleep: sex and age effects in depressed outpatients and healthy controls. <i>Psychiatry Research</i> , 2000 , 95, 201-13	9.9	115
582	Relationship between objective and subjective sleep measures in depressed patients and healthy controls. <i>Depression and Anxiety</i> , 1997 , 5, 97-102	8.4	114
581	Early adversity in chronic depression: clinical correlates and response to pharmacotherapy. <i>Depression and Anxiety</i> , 2009 , 26, 701-10	8.4	113
580	Benzodiazepines as antidepressants: does GABA play a role in depression?. <i>Biological Psychiatry</i> , 1995 , 38, 578-91	7.9	113
579	Factors associated with health-related quality of life among outpatients with major depressive disorder: a STAR*D report. <i>Journal of Clinical Psychiatry</i> , 2006 , 67, 185-95	4.6	113
578	Chronic depression: medication (nefazodone) or psychotherapy (CBASP) is effective when the other is not. <i>Archives of General Psychiatry</i> , 2005 , 62, 513-20		110
577	Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcome. <i>Drug and Alcohol Dependence</i> , 2009 , 99, 248-60	4.9	109
576	Peripheral cytokine levels and response to antidepressant treatment in depression: a systematic review and meta-analysis. <i>Molecular Psychiatry</i> , 2020 , 25, 339-350	15.1	107
575	Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR(*)D measurement-based care. <i>Neuropsychopharmacology</i> , 2007 , 32, 2479-89	8.7	106
574	Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. <i>Archives of General Psychiatry</i> , 2007 , 64, 689-97		106

573	Predictors of attrition during initial (citalopram) treatment for depression: a STAR*D report. <i>American Journal of Psychiatry</i> , 2007 , 164, 1189-97	11.9	106
572	Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. <i>Neuropsychopharmacology</i> , 1999 , 20, 226-47	8.7	105
571	Factors that differentiate early vs. later onset of major depression disorder. <i>Psychiatry Research</i> , 2004 , 129, 127-40	9.9	103
570	The link between depression and physical symptoms. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , 2004 , 6, 12-6		103
569	Children of currently depressed mothers: a STAR*D ancillary study. <i>Journal of Clinical Psychiatry</i> , 2006 , 67, 126-36	4.6	103
568	Clinical evidence and potential neurobiological underpinnings of unresolved symptoms of depression. <i>Journal of Clinical Psychiatry</i> , 2008 , 69, 246-58	4.6	103
567	Insomnia in patients with depression: a STAR*D report. <i>CNS Spectrums</i> , 2010 , 15, 394-404	1.8	102
566	The Texas Children's Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 1999 , 38, 1442-54	7.2	102
565	Measurement-based care in psychiatric practice: a policy framework for implementation. <i>Journal of Clinical Psychiatry</i> , 2011 , 72, 1136-43	4.6	101
564	A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. <i>American Journal of Psychiatry</i> , 2006 , 163, 1161-72	11.9	100
563	Inflammation, obesity, and metabolic syndrome in depression: analysis of the 2009-2010 National Health and Nutrition Examination Survey (NHANES). <i>Journal of Clinical Psychiatry</i> , 2014 , 75, e1428-32	4.6	99
562	Association between bipolar spectrum features and treatment outcomes in outpatients with major depressive disorder. <i>Archives of General Psychiatry</i> , 2011 , 68, 351-60		99
561	Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response. <i>Archives of General Psychiatry</i> , 2010 , 67, 369-79		96
560	Self-reported depressive symptom measures: sensitivity to detecting change in a randomized, controlled trial of chronically depressed, nonpsychotic outpatients. <i>Neuropsychopharmacology</i> , 2005 , 30, 405-16	8.7	96
559	Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder. <i>Psychiatry Research</i> , 2009 , 169, 132-8	9.9	95
558	Test-retest reliability of freesurfer measurements within and between sites: Effects of visual approval process. <i>Human Brain Mapping</i> , 2015 , 36, 3472-85	5.9	94
557	Sulfhydryl-reactive metals in autism. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2007 , 70, 715-21	3.2	91
556	Cognitive-behavioral analysis system of psychotherapy as a maintenance treatment for chronic depression. <i>Journal of Consulting and Clinical Psychology</i> , 2004 , 72, 681-8	6.5	91

555	Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR(*)D study. <i>Neuropsychopharmacology</i> , 2008 , 33, 2810-9	8.7	89
554	Health-related quality of life in depression: a STAR*D report. <i>Annals of Clinical Psychiatry</i> , 2010 , 22, 43-55.4	5.4	89
553	Comparison of self-report and clinician ratings on two inventories of depressive symptomatology. <i>Psychiatric Services</i> , 2006 , 57, 829-37	3.3	85
552	Depression, IV: STAR*D treatment trial for depression. <i>American Journal of Psychiatry</i> , 2003 , 160, 237	11.9	85
551	Increase in work productivity of depressed individuals with improvement in depressive symptom severity. <i>American Journal of Psychiatry</i> , 2013 , 170, 633-41	11.9	84
550	The effects of psychotherapy, nefazodone, and their combination on subjective assessment of disturbed sleep in chronic depression. <i>Sleep</i> , 2003 , 26, 130-6	1.1	83
549	Clinical features of depressed outpatients with and without co-occurring general medical conditions in STAR*D. <i>General Hospital Psychiatry</i> , 2004 , 26, 421-9	5.6	83
548	The effects of nefazodone on sleep architecture in depression. <i>Neuropsychopharmacology</i> , 1994 , 10, 123-7	8.7	83
547	Complementary and alternative medicine in major depressive disorder: the American Psychiatric Association Task Force report. <i>Journal of Clinical Psychiatry</i> , 2010 , 71, 669-81	4.6	82
546	Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a consensus statement. <i>Journal of Clinical Psychiatry</i> , 2010 , 71, e1-e21	4.6	81
545	Symptom features of postpartum depression: are they distinct?. <i>Depression and Anxiety</i> , 2008 , 25, 20-6	8.4	81
544	Concise Health Risk Tracking scale: a brief self-report and clinician rating of suicidal risk. <i>Journal of Clinical Psychiatry</i> , 2011 , 72, 757-64	4.6	81
543	Pretreatment Rostral Anterior Cingulate Cortex Theta Activity in Relation to Symptom Improvement in Depression: A Randomized Clinical Trial. <i>JAMA Psychiatry</i> , 2018 , 75, 547-554	14.5	80
542	Response to a selective serotonin reuptake inhibitor (citalopram) in major depressive disorder with melancholic features: a STAR*D report. <i>Journal of Clinical Psychiatry</i> , 2008 , 69, 1847-55	4.6	80
541	Screening and Management of Depression in Patients With Cardiovascular Disease: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 1827-1845	15.1	79
540	Major depression symptoms in primary care and psychiatric care settings: a cross-sectional analysis. <i>Annals of Family Medicine</i> , 2007 , 5, 126-34	2.9	79
539	Brief psychiatric rating scale expanded version: How do new items affect factor structure?. <i>Psychiatry Research</i> , 2005 , 135, 217-28	9.9	78
538	One-year clinical outcomes of depressed public sector outpatients: a benchmark for subsequent studies. <i>Biological Psychiatry</i> , 2004 , 56, 46-53	7.9	77

537	Treatment-resistant depression. <i>Journal of Clinical Psychiatry</i> , 2006 , 67 Suppl 6, 16-22	4.6	76
536	Psychometric properties of the Quick Inventory of Depressive Symptomatology in adolescents. <i>International Journal of Methods in Psychiatric Research</i> , 2010 , 19, 185-94	4.3	75
535	Evidence-based recommendations for the prescription of exercise for major depressive disorder. <i>Journal of Psychiatric Practice</i> , 2013 , 19, 204-12	1.3	74
534	Primary versus specialty care outcomes for depressed outpatients managed with measurement-based care: results from STAR*D. <i>Journal of General Internal Medicine</i> , 2008 , 23, 551-60	4	74
533	Measurement-based care for refractory depression: a clinical decision support model for clinical research and practice. <i>Drug and Alcohol Dependence</i> , 2007 , 88 Suppl 2, S61-71	4.9	74
532	Texas Medication Algorithm Project, phase 3 (TMAP-3): rationale and study design. <i>Journal of Clinical Psychiatry</i> , 2003 , 64, 357-69	4.6	74
531	Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: an examination of citalopram in the STAR*D study. <i>Journal of Affective Disorders</i> , 2009 , 117, 63-73	6.6	73
530	Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder. <i>Biological Psychiatry</i> , 2009 , 65, 785-91	7.9	73
529	The DOSE study: a clinical trial to examine efficacy and dose response of exercise as treatment for depression. <i>Contemporary Clinical Trials</i> , 2002 , 23, 584-603		73
528	The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases. <i>Journal of Clinical Psychiatry</i> , 2007 , 68, 1246-56	4.6	73
527	Personalized prediction of antidepressant v. placebo response: evidence from the EMBARC study. <i>Psychological Medicine</i> , 2019 , 49, 1118-1127	6.9	72
526	Remission, response without remission, and nonresponse in major depressive disorder: impact on functioning. <i>International Clinical Psychopharmacology</i> , 2009 , 24, 133-8	2.2	72
525	Substance use disorder comorbidity in major depressive disorder: a confirmatory analysis of the STAR*D cohort. <i>American Journal on Addictions</i> , 2006 , 15, 278-85	3.7	70
524	The Texas medication algorithm project: clinical results for schizophrenia. <i>Schizophrenia Bulletin</i> , 2004 , 30, 627-47	1.3	69
523	Texas Medication Algorithm Project, phase 3 (TMAP-3): clinical results for patients with a history of mania. <i>Journal of Clinical Psychiatry</i> , 2003 , 64, 370-82	4.6	69
522	An electroencephalographic signature predicts antidepressant response in major depression. <i>Nature Biotechnology</i> , 2020 , 38, 439-447	44.5	68
521	Course and Severity of Maternal Depression: Associations with Family Functioning and Child Adjustment. <i>Journal of Youth and Adolescence</i> , 2008 , 37, 906-916	4.5	68
520	A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder. <i>Journal of Clinical Psychiatry</i> , 2015 , 76, 575-82	4.6	68

519	Moderation of the Relationship Between Reward Expectancy and Prediction Error-Related Ventral Striatal Reactivity by Anhedonia in Unmedicated Major Depressive Disorder: Findings From the EMBARC Study. <i>American Journal of Psychiatry</i> , 2015 , 172, 881-91	11.9	67
518	Peripheral biomarkers of major depression and antidepressant treatment response: Current knowledge and future outlooks. <i>Journal of Affective Disorders</i> , 2018 , 233, 3-14	6.6	67
517	Psychometric evaluation of the Snaith-Hamilton pleasure scale in adult outpatients with major depressive disorder. <i>International Clinical Psychopharmacology</i> , 2010 , 25, 328-33	2.2	67
516	Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial. <i>Journal of Clinical Psychiatry</i> , 2001 , 62, 413-20	4.6	67
515	Childhood trauma history is linked to abnormal brain connectivity in major depression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019 , 116, 8582-8590	11.5	66
514	A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. <i>Psychopharmacology</i> , 2015 , 232, 2061-70	4.7	66
513	Painful physical symptoms and treatment outcome in major depressive disorder: a STAR*D (Sequenced Treatment Alternatives to Relieve Depression) report. <i>Psychological Medicine</i> , 2010 , 40, 239-51	6.9	66
512	Systematic use of patient-rated depression severity monitoring: is it helpful and feasible in clinical psychiatry?. <i>Psychiatric Services</i> , 2008 , 59, 1148-54	3.3	66
511	Is unrecognized bipolar disorder a frequent contributor to apparent treatment resistant depression?. <i>Journal of Affective Disorders</i> , 2010 , 127, 10-8	6.6	65
510	Medication treatment for the severely and persistently mentally ill: the Texas Medication Algorithm Project. <i>Journal of Clinical Psychiatry</i> , 1999 , 60, 284-91	4.6	65
509	Pain in depression: STAR*D study findings. <i>Journal of Psychosomatic Research</i> , 2007 , 63, 113-22	4.1	64
508	Effects of serum Brain Derived Neurotrophic Factor on exercise augmentation treatment of depression. <i>Journal of Psychiatric Research</i> , 2011 , 45, 1301-6	5.2	63
507	Neural Correlates of Three Promising Endophenotypes of Depression: Evidence from the EMBARC Study. <i>Neuropsychopharmacology</i> , 2016 , 41, 454-63	8.7	62
506	Effect of Sertraline on Depressive Symptoms in Patients With Chronic Kidney Disease Without Dialysis Dependence: The CAST Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 318, 1876-1890	27.4	61
505	Irritability is associated with anxiety and greater severity, but not bipolar spectrum features, in major depressive disorder. <i>Acta Psychiatrica Scandinavica</i> , 2009 , 119, 282-9	6.5	61
504	Influences of hormone-based contraception on depressive symptoms in premenopausal women with major depression. <i>Psychoneuroendocrinology</i> , 2007 , 32, 843-53	5	61
503	Chronic forms of major depression are still undertreated in the 21st century: systematic assessment of 801 patients presenting for treatment. <i>Journal of Affective Disorders</i> , 2008 , 110, 55-61	6.6	60
502	TREAD: Treatment with Exercise Augmentation for Depression: study rationale and design. <i>Clinical Trials</i> , 2006 , 3, 291-305	2.2	60

501	Assessing insomnia severity in depression: comparison of depression rating scales and sleep diaries. <i>Journal of Psychiatric Research</i> , 2005 , 39, 481-8	5.2	60
500	Temporal Characteristics of Delta Activity During NREM Sleep in Depressed Outpatients and Healthy Adults: Group and Sex Effects. <i>Sleep</i> , 2000 , 23, 1-11	1.1	60
499	Does comorbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STAR*D level one treatment outcomes. <i>Drug and Alcohol Dependence</i> , 2010 , 107, 161-70	4.9	59
498	Clinical differences among depressed patients with and without a history of suicide attempts: findings from the STAR*D trial. <i>Journal of Affective Disorders</i> , 2007 , 97, 77-84	6.6	59
497	Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression. <i>Biological Psychiatry</i> , 2003 , 54, 806-17	7.9	59
496	Self-reported premenstrual exacerbation of depressive symptoms in patients seeking treatment for major depression. <i>Psychological Medicine</i> , 2005 , 35, 683-92	6.9	59
495	Prenatal depression in women hospitalized for obstetric risk. <i>Journal of Clinical Psychiatry</i> , 2008 , 69, 635-48	4.8	59
494	What predicts attrition in second step medication treatments for depression?: a STAR*D Report. <i>International Journal of Neuropsychopharmacology</i> , 2009 , 12, 459-73	5.8	58
493	The history and current state of antidepressant clinical trial design: a call to action for proof-of-concept studies. <i>Journal of Clinical Psychiatry</i> , 2008 , 69, 1513-28	4.6	58
492	A randomized, double-blind, placebo-controlled study of the efficacy and safety of 2 doses of vortioxetine in adults with major depressive disorder. <i>Journal of Clinical Psychiatry</i> , 2015 , 76, 583-91	4.6	57
491	Acceptability of second-step treatments to depressed outpatients: a STAR*D report. <i>American Journal of Psychiatry</i> , 2007 , 164, 753-60	11.9	56
490	Development and Implementation of Computerized Clinical Guidelines: Barriers and Solutions. <i>Methods of Information in Medicine</i> , 2002 , 41, 435-442	1.5	56
489	A direct comparison of presenting characteristics of depressed outpatients from primary vs. specialty care settings: preliminary findings from the STAR*D clinical trial. <i>General Hospital Psychiatry</i> , 2005 , 27, 87-96	5.6	56
488	A computerized clinical decision support system as a means of implementing depression guidelines. <i>Psychiatric Services</i> , 2004 , 55, 879-85	3.3	54
487	Tools and strategies for ongoing assessment of depression: a measurement-based approach to remission. <i>Journal of Clinical Psychiatry</i> , 2009 , 70 Suppl 6, 26-31	4.6	54
486	Bupropion and Naltrexone in Methamphetamine Use Disorder. <i>New England Journal of Medicine</i> , 2021 , 384, 140-153	59.2	54
485	Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder. <i>Neuropsychopharmacology</i> , 2014 , 39, 1388-98	8.7	53
484	Barriers to implementation of a computerized decision support system for depression: an observational report on lessons learned in "real world" clinical settings. <i>BMC Medical Informatics and Decision Making</i> , 2009 , 9, 6	3.6	53

483	Prevalence and Clinical Correlates of Irritability in Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2005 , 66, 159-166	4.6	53
482	Treatment strategies to improve and sustain remission in major depressive disorder. <i>Dialogues in Clinical Neuroscience</i> , 2008 , 10, 377-84	5.7	52
481	Treating Depression to Remission. <i>Psychiatric Annals</i> , 1995 , 25, 704-709	0.5	51
480	Strategies to enhance the therapeutic efficacy of antidepressants: targeting residual symptoms. <i>Expert Review of Neurotherapeutics</i> , 2009 , 9, 975-84	4.3	50
479	Long-term tolerability and effectiveness of duloxetine in the treatment of major depressive disorder. <i>Depression and Anxiety</i> , 2008 , 25, E1-8	8.4	50
478	The Texas Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 1999 , 60, 142-56	4.6	50
477	Predictors of attrition with buprenorphine/naloxone treatment in opioid dependent youth. <i>Addictive Behaviors</i> , 2012 , 37, 1046-53	4.2	49
476	Family history of mood disorder and characteristics of major depressive disorder: a STAR*D (sequenced treatment alternatives to relieve depression) study. <i>Journal of Psychiatric Research</i> , 2007 , 41, 214-21	5.2	49
475	Baseline depression severity as a predictor of single and combination antidepressant treatment outcome: results from the CO-MED trial. <i>European Neuropsychopharmacology</i> , 2012 , 22, 183-99	1.2	48
474	Epidemiology of nonfatal deliberate self-harm in the United States as described in three medical databases. <i>Suicide and Life-Threatening Behavior</i> , 2006 , 36, 192-212	3.9	48
473	Interleukin 17 selectively predicts better outcomes with bupropion-SSRI combination: Novel T cell biomarker for antidepressant medication selection. <i>Brain, Behavior, and Immunity</i> , 2017 , 66, 103-110	16.6	47
472	Exercise in the treatment of depression. <i>Current Psychiatry Reports</i> , 2009 , 11, 466-72	9.1	47
471	Remission of maternal depression: relations to family functioning and youth internalizing and externalizing symptoms. <i>Journal of Clinical Child and Adolescent Psychology</i> , 2008 , 37, 714-24	5.4	47
470	Personalized Antidepressant Selection and Pathway to Novel Treatments: Clinical Utility of Targeting Inflammation. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	46
469	Dyadic discord at baseline is associated with lack of remission in the acute treatment of chronic depression. <i>Psychological Medicine</i> , 2010 , 40, 415-24	6.9	46
468	Is prior course of illness relevant to acute or longer-term outcomes in depressed out-patients? A STAR*D report. <i>Psychological Medicine</i> , 2012 , 42, 1131-49	6.9	46
467	Efficacy of porcine secretin in children with autism and pervasive developmental disorder. <i>Journal of Autism and Developmental Disorders</i> , 2002 , 32, 153-60	4.6	46
466	Double-blind, placebo-substitution study of nefazodone in the prevention of relapse during continuation treatment of outpatients with major depression. <i>International Clinical Psychopharmacology</i> , 1999 , 14, 19-28	2.2	46

465	Factors predicting reduced antidepressant response: experience with the SNRI duloxetine in patients with major depression. <i>Annals of Clinical Psychiatry</i> , 2008 , 20, 209-18	1.4	45
464	Effects of fluoxetine on the polysomnogram in outpatients with major depression. <i>Neuropsychopharmacology</i> , 1999 , 20, 447-59	8.7	45
463	Predictors of abstinence: National Institute of Drug Abuse multisite buprenorphine/naloxone treatment trial in opioid-dependent youth. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2011 , 50, 1120-8	7.2	44
462	Functional connectivity of brain structures correlates with treatment outcome in major depressive disorder. <i>Frontiers in Psychiatry</i> , 2011 , 2, 7	5	44
461	Folate and unipolar depression. <i>Journal of Alternative and Complementary Medicine</i> , 2008 , 14, 277-85	2.4	44
460	Faster remission of chronic depression with combined psychotherapy and medication than with each therapy alone. <i>Journal of Consulting and Clinical Psychology</i> , 2008 , 76, 459-67	6.5	44
459	Preadult onset vs. adult onset of major depressive disorder: a replication study. <i>Acta Psychiatrica Scandinavica</i> , 2007 , 115, 196-205	6.5	44
458	Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a brief report. <i>Journal of Clinical Psychiatry</i> , 2010 , 71, 1040-6	4.6	44
457	Clinical features of depression in outpatients with and without co-occurring general medical conditions in STAR*D: confirmatory analysis. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , 2007 , 9, 7-15		44
456	The influence of menopause status and postmenopausal use of hormone therapy on presentation of major depression in women. <i>Menopause</i> , 2010 , 17, 828-39	2.5	43
455	Ethnicity/race and outcome in the treatment of depression: results from STAR*D. <i>Medical Care</i> , 2007 , 45, 1043-51	3.1	43
454	Comparative Efficacy of Therapies for Treatment of Depression for Patients Undergoing Maintenance Hemodialysis: A Randomized Clinical Trial. <i>Annals of Internal Medicine</i> , 2019 , 170, 369-379	8	43
453	Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report. <i>Journal of Affective Disorders</i> , 2011 , 133, 467-76	6.6	42
452	Examining sensory quadrants in autism. <i>Research in Autism Spectrum Disorders</i> , 2007 , 1, 185-193	3	42
451	An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression. <i>Journal of Clinical Psychiatry</i> , 2009 , 70, 387-96	4.6	42
450	Concise Associated Symptoms Tracking scale: a brief self-report and clinician rating of symptoms associated with suicidality. <i>Journal of Clinical Psychiatry</i> , 2011 , 72, 765-74	4.6	42
449	Decline in cardiorespiratory fitness and odds of incident depression. <i>American Journal of Preventive Medicine</i> , 2012 , 43, 361-8	6.1	41
448	Do atypical features affect outcome in depressed outpatients treated with citalopram?. <i>International Journal of Neuropsychopharmacology</i> , 2010 , 13, 15-30	5.8	41

447	Sex differences in the distribution of EEG frequencies during sleep: unipolar depressed outpatients. <i>Journal of Affective Disorders</i> , 1995 , 34, 121-9	6.6	41
446	Symptom clusters as predictors of late response to antidepressant treatment. <i>Journal of Clinical Psychiatry</i> , 2005 , 66, 1064-70	4.6	41
445	Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study. <i>Journal of Clinical Psychiatry</i> , 2007 , 68, 1014-23	4.6	41
444	Dose-dependent changes in cognitive function with exercise augmentation for major depression: results from the TREAD study. <i>European Neuropsychopharmacology</i> , 2015 , 25, 248-56	1.2	40
443	Factor structure and dimensionality of the two depression scales in STAR*D using level 1 datasets. <i>Journal of Affective Disorders</i> , 2011 , 132, 396-400	6.6	40
442	Clinical vs. self-report versions of the quick inventory of depressive symptomatology in a public sector sample. <i>Journal of Psychiatric Research</i> , 2007 , 41, 239-46	5.2	40
441	Pattern recognition analysis of anterior cingulate cortex blood flow to classify depression polarity. <i>British Journal of Psychiatry</i> , 2013 , 203, 310-1	5.4	39
440	Income and attrition in the treatment of depression: a STAR*D report. <i>Depression and Anxiety</i> , 2009 , 26, 622-33	8.4	39
439	Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder. <i>Journal of Clinical Psychiatry</i> , 2004 , 65, 1356-64	4.6	39
438	Demonstrating test-retest reliability of electrophysiological measures for healthy adults in a multisite study of biomarkers of antidepressant treatment response. <i>Psychophysiology</i> , 2017 , 54, 34-50	4.1	38
437	Randomized Controlled Trial Comparing Exercise to Health Education for Stimulant Use Disorder: Results From the CTN-0037 STimulant Reduction Intervention Using Dosed Exercise (STRIDE) Study. <i>Journal of Clinical Psychiatry</i> , 2017 , 78, 1075-1082	4.6	38
436	Web-based communications and management of a multi-center clinical trial: the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) project. <i>Clinical Trials</i> , 2004 , 1, 387-98	2.2	38
435	Fluoxetine and oculomotor activity during sleep in depressed patients. <i>Neuropsychopharmacology</i> , 1995 , 12, 159-65	8.7	38
434	Prospective trial of equine-assisted activities in autism spectrum disorder. <i>Alternative Therapies in Health and Medicine</i> , 2011 , 17, 14-20	2.5	38
433	Cognitive therapy for anxious depression in STAR(*) D: what have we learned?. <i>Journal of Affective Disorders</i> , 2012 , 142, 213-8	6.6	37
432	Stimulant reduction intervention using dosed exercise (STRIDE) - CTN 0037: study protocol for a randomized controlled trial. <i>Trials</i> , 2011 , 12, 206	2.8	37
431	Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine. <i>International Clinical Psychopharmacology</i> , 2008 , 23, 161-9	2.2	37
430	Does provider adherence to a treatment guideline change clinical outcomes for patients with bipolar disorder? Results from the Texas Medication Algorithm Project. <i>Psychological Medicine</i> , 2005 , 35, 1695-706	6.9	37

429	A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram. <i>Journal of Clinical Psychiatry</i> , 2013 , 74, 802-9	4.6	37
428	Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients?. <i>Journal of Clinical Psychiatry</i> , 2001 , 62, 776-81	4.6	37
427	Pharmacological Treatments for Patients with Treatment-Resistant Depression. <i>Pharmaceuticals</i> , 2020 , 13,	5.2	36
426	Two Trajectories of Depressive Symptom Reduction Throughout Behavioral Activation Teletherapy Among Underserved, Ethnically Diverse, Primary Care Patients: A VitalSign Report. <i>Behavior Therapy</i> , 2020 , 51, 958-971	4.8	36
425	Does exercise improve self-reported sleep quality in non-remitted major depressive disorder?. <i>Psychological Medicine</i> , 2013 , 43, 699-709	6.9	36
424	Does duloxetine improve cognitive function independently of its antidepressant effect in patients with major depressive disorder and subjective reports of cognitive dysfunction?. <i>Depression Research and Treatment</i> , 2014 , 2014, 627863	3.8	36
423	Antenatal depression: a rationale for studying exercise. <i>Depression and Anxiety</i> , 2011 , 28, 234-42	8.4	35
422	Effect of 11 September 2001 terrorist attacks in the USA on suicide in areas surrounding the crash sites. <i>British Journal of Psychiatry</i> , 2010 , 196, 359-64	5.4	35
421	Adjunctive Aripiprazole in Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2008 , 69, 1928-1936	4.6	35
420	Relationship between obesity and depression: characteristics and treatment outcomes with antidepressant medication. <i>Psychosomatic Medicine</i> , 2013 , 75, 863-72	3.7	34
419	Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED trial report. <i>Psychological Medicine</i> , 2013 , 43, 945-60	6.9	34
418	Concordance between clinician and patient ratings as predictors of response, remission, and recurrence in major depressive disorder. <i>Journal of Psychiatric Research</i> , 2011 , 45, 96-103	5.2	34
417	Abnormal brain response to cholinergic challenge in chronic encephalopathy from the 1991 Gulf War. <i>Psychiatry Research - Neuroimaging</i> , 2009 , 171, 207-20	2.9	34
416	An open pilot study of the combination of escitalopram and bupropion-SR for outpatients with major depressive disorder. <i>Journal of Psychiatric Practice</i> , 2008 , 14, 271-80	1.3	34
415	A psychometric evaluation of the CDRS and MADRS in assessing depressive symptoms in children. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2007 , 46, 1204-1212	7.2	34
414	Effect of antidepressant medication treatment on suicidal ideation and behavior in a randomized trial: an exploratory report from the Combining Medications to Enhance Depression Outcomes Study. <i>Journal of Clinical Psychiatry</i> , 2011 , 72, 1322-32	4.6	34
413	Differential effects of nefazodone and cognitive behavioral analysis system of psychotherapy on insomnia associated with chronic forms of major depression. <i>Journal of Clinical Psychiatry</i> , 2002 , 63, 493-500	4.6	34
412	Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, psychotherapy, and their combination. <i>Journal of Clinical Psychiatry</i> , 2002 , 63, 709-16	4.6	34

411	Regional cerebral blood flow response to oral amphetamine challenge in healthy volunteers. <i>Journal of Nuclear Medicine</i> , 2001 , 42, 535-42	8.9	34
410	Early Improvement in Work Productivity Predicts Future Clinical Course in Depressed Outpatients: Findings From the CO-MED Trial. <i>American Journal of Psychiatry</i> , 2016 , 173, 1196-1204	11.9	33
409	Depression outcomes in psychiatric clinical practice: using a self-rated measure of depression severity. <i>Psychiatric Services</i> , 2011 , 62, 929-35	3.3	33
408	Fractional anisotropy changes after several weeks of daily left high-frequency repetitive transcranial magnetic stimulation of the prefrontal cortex to treat major depression. <i>Journal of ECT</i> , 2011 , 27, 5-10	2	33
407	The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases. <i>Biological Psychiatry</i> , 2007 , 62, 1371-9	7.9	33
406	Response in relation to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertraline. <i>Neuropsychopharmacology</i> , 2001 , 25, 131-8	8.7	33
405	Examining the efficacy of adjunctive aripiprazole in major depressive disorder: a pooled analysis of 2 studies. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , 2008 , 10, 440-7		33
404	Reduced anti-inflammatory gut microbiota are associated with depression and anhedonia. <i>Journal of Affective Disorders</i> , 2020 , 266, 394-401	6.6	33
403	Consensus recommendations for improving adherence, self-management, and outcomes in patients with depression. <i>CNS Spectrums</i> , 2007 , 12, 1-27	1.8	33
402	Validating pre-treatment body mass index as moderator of antidepressant treatment outcomes: Findings from CO-MED trial. <i>Journal of Affective Disorders</i> , 2018 , 234, 34-37	6.6	32
401	A COMPREHENSIVE EXAMINATION OF WHITE MATTER TRACTS AND CONNECTOMETRY IN MAJOR DEPRESSIVE DISORDER. <i>Depression and Anxiety</i> , 2016 , 33, 56-65	8.4	32
400	A computational analysis of flanker interference in depression. <i>Psychological Medicine</i> , 2015 , 45, 2333-44	6.9	32
399	Treatment outcomes for older depressed patients with earlier versus late onset of first depressive episode: a Sequenced Treatment Alternatives to Relieve Depression (STAR*D) report. <i>American Journal of Geriatric Psychiatry</i> , 2008 , 16, 58-64	6.5	32
398	A computerized decision support system for depression in primary care. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , 2009 , 11, 140-6		32
397	Opioid withdrawal, craving, and use during and after outpatient buprenorphine stabilization and taper: a discrete survival and growth mixture model. <i>Addictive Behaviors</i> , 2015 , 41, 20-8	4.2	31
396	Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2011 , 7, 303-12	3.1	31
395	Does the duration of index episode affect the treatment outcome of major depressive disorder? A STAR*D report. <i>Journal of Clinical Psychiatry</i> , 2008 , 69, 1246-56	4.6	31
394	Psychopharmacological Treatment in the RAISE-ETP Study: Outcomes of a Manual and Computer Decision Support System Based Intervention. <i>American Journal of Psychiatry</i> , 2018 , 175, 169-179	11.9	30

393	Exercise is an effective treatment for positive valence symptoms in major depression. <i>Journal of Affective Disorders</i> , 2017 , 209, 188-194	6.6	30
392	Brief, unidimensional melancholia rating scales are highly sensitive to the effect of citalopram and may have biological validity: implications for the research domain criteria (RDoC). <i>Journal of Affective Disorders</i> , 2014 , 163, 18-24	6.6	30
391	Do menopausal status and use of hormone therapy affect antidepressant treatment response? Findings from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. <i>Journal of Women's Health</i> , 2013 , 22, 121-31	3	30
390	Psychosocial outcomes in patients with recurrent major depressive disorder during 2 years of maintenance treatment with venlafaxine extended release. <i>Journal of Affective Disorders</i> , 2010 , 126, 420-9	6.6	30
389	What moderator characteristics are associated with better prognosis for depression?. <i>Neuropsychiatric Disease and Treatment</i> , 2005 , 1, 51-7	3.1	30
388	Pretreatment and early-treatment cortical thickness is associated with SSRI treatment response in major depressive disorder. <i>Neuropsychopharmacology</i> , 2018 , 43, 2221-2230	8.7	29
387	Olanzapine/fluoxetine combination in patients with treatment-resistant depression: rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies. <i>Journal of Clinical Psychiatry</i> , 2010 , 71, 451-62	4.6	29
386	Diurnal Mood Variation in Outpatients With Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2007 , 68, 1339-1347	4.6	29
385	Effect of Intrinsic Patterns of Functional Brain Connectivity in Moderating Antidepressant Treatment Response in Major Depression. <i>American Journal of Psychiatry</i> , 2020 , 177, 143-154	11.9	29
384	A Novel Strategy to Identify Placebo Responders: Prediction Index of Clinical and Biological Markers in the EMBARC Trial. <i>Psychotherapy and Psychosomatics</i> , 2018 , 87, 285-295	9.4	28
383	Depression treatment in patients with general medical conditions: results from the CO-MED trial. <i>Annals of Family Medicine</i> , 2012 , 10, 23-33	2.9	28
382	Response to vestibular sensory events in autism. <i>Research in Autism Spectrum Disorders</i> , 2007 , 1, 67-74	3	28
381	A comparison of alternative assessments of depressive symptom severity: a pilot study. <i>Psychiatry Research</i> , 2000 , 96, 269-79	9.9	28
380	Identification of psychiatric disorder subtypes from functional connectivity patterns in resting-state electroencephalography. <i>Nature Biomedical Engineering</i> , 2021 , 5, 309-323	19	28
379	Association of Midlife Cardiorespiratory Fitness With Incident Depression and Cardiovascular Death After Depression in Later Life. <i>JAMA Psychiatry</i> , 2018 , 75, 911-917	14.5	28
378	Outcomes on the pharmacopsychometric triangle in bupropion-SR vs. buspirone augmentation of citalopram in the STAR*D trial. <i>Acta Psychiatrica Scandinavica</i> , 2012 , 125, 342-8	6.5	27
377	Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: a meta-analysis of individual patient data from 10 double-blind, randomized clinical trials. <i>Journal of Psychiatric Research</i> , 2008 , 42, 134-40	5.2	27
376	Making clinicians lives easier: guidance on use of the QIDS self-report in place of the MADRS. <i>Journal of Affective Disorders</i> , 2006 , 95, 115-8	6.6	27

375	Comparison of quality of life measures in a depressed population. <i>Journal of Nervous and Mental Disease</i> , 2007 , 195, 219-25	1.8	27
374	Prevention of missing data in clinical research studies. <i>Biological Psychiatry</i> , 2006 , 59, 997-1000	7.9	27
373	Temporal characteristics of delta activity during NREM sleep in depressed outpatients and healthy adults: group and sex effects. <i>Sleep</i> , 2000 , 23, 607-17	1.1	27
372	Rationale and design of A Trial of Sertraline vs. Cognitive Behavioral Therapy for End-stage Renal Disease Patients with Depression (ASCEND). <i>Contemporary Clinical Trials</i> , 2016 , 47, 1-11	2.3	26
371	Preliminary evidence that early reduction in p11 levels in natural killer cells and monocytes predicts the likelihood of antidepressant response to chronic citalopram. <i>Molecular Psychiatry</i> , 2014 , 19, 962-4	15.1	26
370	Diagnostic utility of the Quick Inventory of Depressive Symptomatology (QIDS-C16 and QIDS-SR16) in the elderly. <i>Acta Psychiatrica Scandinavica</i> , 2010 , 122, 226-34	6.5	26
369	Depression outcomes of Spanish- and english-speaking Hispanic outpatients in STAR*D. <i>Psychiatric Services</i> , 2008 , 59, 1273-84	3.3	26
368	Remission of maternal depression and child symptoms among single mothers: a STAR*D-Child report. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2007 , 42, 962-71	4.5	26
367	Catching up on health outcomes: the Texas Medication Algorithm Project. <i>Health Services Research</i> , 2003 , 38, 311-31	3.4	26
366	Influence of sex and menopausal status on response, remission, and recurrence in patients with recurrent major depressive disorder treated with venlafaxine extended release or fluoxetine: analysis of data from the PREVENT study. <i>Journal of Clinical Psychiatry</i> , 2014 , 75, 62-8	4.6	26
365	Association of T and non-T cell cytokines with anhedonia: Role of gender differences. <i>Psychoneuroendocrinology</i> , 2018 , 95, 1-7	5	26
364	Development and implementation of computerized clinical guidelines: barriers and solutions. <i>Methods of Information in Medicine</i> , 2002 , 41, 435-42	1.5	26
363	Clinical and sociodemographic characteristics associated with suicidal ideation in depressed outpatients. <i>Canadian Journal of Psychiatry</i> , 2013 , 58, 113-22	4.8	25
362	Sociodemographic, clinical, and treatment characteristics associated with worsened depression during treatment with citalopram: results of the NIMH STAR(*)D trial. <i>Depression and Anxiety</i> , 2009 , 26, 612-21	8.4	25
361	Effects of race and ethnicity on depression treatment outcomes: the CO-MED trial. <i>Psychiatric Services</i> , 2011 , 62, 1167-79	3.3	25
360	Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies. <i>Journal of Clinical Psychopharmacology</i> , 2008 , 28, 308-16	1.7	25
359	Response to Zhang et al. (2005): loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. <i>Neuron</i> 45, 11-16. <i>Neuron</i> , 2005 , 48, 702-3; author reply 705-6	13.9	25
358	Characteristics of insured and noninsured outpatients with depression in STAR(*)D. <i>Psychiatric Services</i> , 2005 , 56, 995-1004	3.3	25

357	Sex differences in response to ketamine as a rapidly acting intervention for treatment resistant depression. <i>Journal of Psychiatric Research</i> , 2019 , 110, 166-171	5.2	24
356	Major depressive disorder and comorbid cardiac disease: is there a depressive subtype with greater cardiovascular morbidity? Results from the STAR*D study. <i>Psychosomatics</i> , 2007 , 48, 418-25	2.6	24
355	Quantitative electroencephalogram biomarkers for predicting likelihood and speed of achieving sustained remission in major depression: a report from the biomarkers for rapid identification of treatment effectiveness in major depression (BRITE-MD) trial. <i>Journal of Clinical Psychiatry</i> , 2013 , 74, 51-6	4.6	24
354	Exercise and mental illness: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). <i>Journal of Clinical Psychiatry</i> , 2012 , 73, 960-6	4.6	24
353	Opioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: two randomized controlled studies. <i>Molecular Psychiatry</i> , 2020 , 25, 1580-1591	15.1	24
352	Continuation treatment of chronic depression: a comparison of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination. <i>Psychopharmacology Bulletin</i> , 2003 , 37, 73-87	0.9	24
351	Major depressive disorder: remission of associated symptoms. <i>Journal of Clinical Psychiatry</i> , 2006 , 67 Suppl 6, 27-32	4.6	24
350	A clinical measure of suicidal ideation, suicidal behavior, and associated symptoms in bipolar disorder: Psychometric properties of the Concise Health Risk Tracking Self-Report (CHRT-SR). <i>Journal of Psychiatric Research</i> , 2015 , 71, 126-33	5.2	23
349	Development and evaluation of a multimodal marker of major depressive disorder. <i>Human Brain Mapping</i> , 2018 , 39, 4420-4439	5.9	23
348	Examining sensory modulation in individuals with autism as compared to community controls. <i>Research in Autism Spectrum Disorders</i> , 2008 , 2, 85-94	3	23
347	Treatment-Resistant Depression: New Therapies on the Horizon. <i>Annals of Clinical Psychiatry</i> , 2003 , 15, 59-70	1.4	23
346	The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations. <i>Journal of Clinical Psychiatry</i> , 2012 , 73, 967-76	4.6	23
345	Exercise for mood and anxiety disorders. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , 2007 , 9, 287-94		23
344	Definition of treatment-resistant depression - Asia Pacific perspectives. <i>Journal of Affective Disorders</i> , 2019 , 245, 626-636	6.6	23
343	Time for united action on depression: a Lancet-World Psychiatric Association Commission.. <i>Lancet, The</i> , 2022 , 399, 957-1022	4.0	23
342	Sex differences in the association of baseline c-reactive protein (CRP) and acute-phase treatment outcomes in major depressive disorder: Findings from the EMBARC study. <i>Journal of Psychiatric Research</i> , 2019 , 113, 165-171	5.2	22
341	ABCB1 (MDR1) predicts remission on P-gp substrates in chronic depression. <i>Pharmacogenomics Journal</i> , 2015 , 15, 332-9	3.5	22
340	Prospective, randomized, double-blind assessment of topical bakuchiol and retinol for facial photoageing. <i>British Journal of Dermatology</i> , 2019 , 180, 289-296	4	22

339	Rationale and design of the Chronic Kidney Disease Antidepressant Sertraline Trial (CAST). <i>Contemporary Clinical Trials</i> , 2013 , 34, 136-44	2.3	22
338	Modeling predictors, moderators and mediators of treatment outcome and resistance in depression. <i>Biological Psychiatry</i> , 2013 , 74, 2-4	7.9	22
337	Predictors of attrition during one year of depression treatment: a roadmap to personalized intervention. <i>Journal of Psychiatric Practice</i> , 2009 , 15, 113-24	1.3	22
336	Growth hormone response to the GABAB agonist baclofen in major depressive disorder. <i>Psychoneuroendocrinology</i> , 1997 , 22, 129-40	5	22
335	Suicide risk management for the sequenced treatment alternatives to relieve depression study: applied NIMH guidelines. <i>Journal of Psychiatric Research</i> , 2004 , 38, 583-9	5.2	22
334	Which depressed patients respond to nefazodone and when?. <i>Journal of Clinical Psychiatry</i> , 2001 , 62, 158-63	4.6	22
333	Symptomatic and syndromal anxiety in chronic forms of major depression: effect of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination. <i>Journal of Clinical Psychiatry</i> , 2002 , 63, 434-41	4.6	22
332	Cortical Connectivity Moderators of Antidepressant vs Placebo Treatment Response in Major Depressive Disorder: Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Psychiatry</i> , 2020 , 77, 397-408	14.5	22
331	Prediction of treatment outcomes to exercise in patients with nonremitted major depressive disorder. <i>Depression and Anxiety</i> , 2017 , 34, 1116-1122	8.4	21
330	Measurement-based care for unipolar depression. <i>Current Psychiatry Reports</i> , 2011 , 13, 446-58	9.1	21
329	Depressive symptoms and metabolic syndrome in preventive healthcare: the Cooper Center longitudinal study. <i>Metabolic Syndrome and Related Disorders</i> , 2010 , 8, 451-7	2.6	21
328	What have we learned about trial design from NIMH-funded pragmatic trials?. <i>Neuropsychopharmacology</i> , 2010 , 35, 2491-501	8.7	21
327	Safety and Tolerability of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Post Hoc Analysis (studies CN138-139 and CN138-163). <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , 2009 , 11, 344-52		21
326	Impaired delay and trace eyeblink conditioning performance in major depressive disorder. <i>Journal of Affective Disorders</i> , 2005 , 86, 235-45	6.6	21
325	Treating depression to full remission. <i>Journal of Clinical Psychiatry</i> , 2009 , 70, e01	4.6	21
324	Identification of a Signaling Mechanism by Which the Microbiome Regulates Th17 Cell-Mediated Depressive-Like Behaviors in Mice. <i>American Journal of Psychiatry</i> , 2020 , 177, 974-990	11.9	21
323	Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression. <i>Depression and Anxiety</i> , 2019 , 36, 235-243	8.4	21
322	When Discontinuing SSRI Antidepressants Is a Challenge: Management Tips. <i>American Journal of Psychiatry</i> , 2018 , 175, 1176-1184	11.9	21

321	REVAMP - Research Evaluating the Value of Augmenting Medication with Psychotherapy: rationale and design. <i>Psychopharmacology Bulletin</i> , 2008 , 41, 5-33	0.9	21
320	A comparison of structural connectivity in anxious depression versus non-anxious depression. <i>Journal of Psychiatric Research</i> , 2017 , 89, 38-47	5.2	20
319	Proteomics profiling reveals inflammatory biomarkers of antidepressant treatment response: Findings from the CO-MED trial. <i>Journal of Psychiatric Research</i> , 2017 , 94, 1-6	5.2	20
318	Can targeted metabolomics predict depression recovery? Results from the CO-MED trial. <i>Translational Psychiatry</i> , 2019 , 9, 11	8.6	20
317	Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement. <i>World Journal of Biological Psychiatry</i> , 2018 , 19, 330-348	3.8	20
316	Platelet-Derived Growth Factor as an Antidepressant Treatment Selection Biomarker: Higher Levels Selectively Predict Better Outcomes with Bupropion-SSRI Combination. <i>International Journal of Neuropsychopharmacology</i> , 2017 , 20, 919-927	5.8	20
315	What are the clinical implications of new onset or worsening anxiety during the first two weeks of SSRI treatment for depression?. <i>Depression and Anxiety</i> , 2012 , 29, 94-101	8.4	20
314	The clinical relevance of self-reported premenstrual worsening of depressive symptoms in the management of depressed outpatients: a STAR*D report. <i>Journal of Women's Health</i> , 2013 , 22, 219-29	3	20
313	Identifying risk for attrition during treatment for depression. <i>Psychotherapy and Psychosomatics</i> , 2009 , 78, 372-9	9.4	20
312	A Comparison of the QIDS-C16, QIDS-SR16, and the MADRS in an Adult Outpatient Clinical Sample. <i>CNS Spectrums</i> , 2010 , 15, 458-68	1.8	20
311	The impact of diabetes on depression treatment outcomes. <i>General Hospital Psychiatry</i> , 2010 , 32, 33-41	5.6	20
310	Side Effects to Antidepressant Treatment in Patients With Depression and Comorbid Panic Disorder. <i>Journal of Clinical Psychiatry</i> , 2017 , 78, 433-440	4.6	20
309	IMPROVEMENTS IN PSYCHOSOCIAL FUNCTIONING AND HEALTH-RELATED QUALITY OF LIFE FOLLOWING EXERCISE AUGMENTATION IN PATIENTS WITH TREATMENT RESPONSE BUT NONREMITTED MAJOR DEPRESSIVE DISORDER: RESULTS FROM THE TREAD STUDY. <i>Depression and Anxiety</i> , 2016 , 33, 870-81	8.4	20
308	Prevalence and clinical correlates of irritability in major depressive disorder: a preliminary report from the Sequenced Treatment Alternatives to Relieve Depression study. <i>Journal of Clinical Psychiatry</i> , 2005 , 66, 159-66; quiz 147, 273-4	4.6	20
307	Irritability and Its Clinical Utility in Major Depressive Disorder: Prediction of Individual-Level Acute-Phase Outcomes Using Early Changes in Irritability and Depression Severity. <i>American Journal of Psychiatry</i> , 2019 , 176, 358-366	11.9	19
306	Worsening Anxiety, Irritability, Insomnia, or Panic Predicts Poorer Antidepressant Treatment Outcomes: Clinical Utility and Validation of the Concise Associated Symptom Tracking (CAST) Scale. <i>International Journal of Neuropsychopharmacology</i> , 2018 , 21, 325-332	5.8	19
305	Evaluation of anhedonia with the Snaith-Hamilton Pleasure Scale (SHAPS) in adult outpatients with major depressive disorder. <i>Journal of Psychiatric Research</i> , 2015 , 65, 124-30	5.2	19
304	Adherence to antidepressant combinations and monotherapy for major depressive disorder: a CO-MED report of measurement-based care. <i>Journal of Psychiatric Practice</i> , 2014 , 20, 118-32	1.3	19

303	Comparing venlafaxine extended release and fluoxetine for preventing the recurrence of major depression: results from the PREVENT study. <i>Journal of Psychiatric Research</i> , 2011 , 45, 412-20	5.2	19
302	Implementing Guidelines and Systems of Care. <i>Journal of Psychiatric Practice</i> , 1999 , 5, 75-86	1.3	19
301	Pretreatment Rostral Anterior Cingulate Cortex Connectivity With Salience Network Predicts Depression Recovery: Findings From the EMBARC Randomized Clinical Trial. <i>Biological Psychiatry</i> , 2019 , 85, 872-880	7.9	19
300	Test-retest reliability of cerebral blood flow in healthy individuals using arterial spin labeling: Findings from the EMBARC study. <i>Magnetic Resonance Imaging</i> , 2018 , 45, 26-33	3.3	18
299	Diurnal mood variation in outpatients with major depressive disorder. <i>Depression and Anxiety</i> , 2009 , 26, 851-63	8.4	18
298	Correlates and outcomes of depressed out-patients with greater and fewer anxious symptoms: a CO-MED report. <i>International Journal of Neuropsychopharmacology</i> , 2012 , 15, 1387-99	5.8	18
297	The effect of pain on outcomes in a trial of duloxetine treatment of major depressive disorder. <i>Annals of Clinical Psychiatry</i> , 2008 , 20, 187-93	1.4	18
296	Electronic source materials in clinical research: acceptability and validity of symptom self-rating in major depressive disorder. <i>Journal of Psychiatric Research</i> , 2007 , 41, 737-43	5.2	18
295	Regional cerebral blood flow alterations in unipolar depression. <i>Psychiatry Research - Neuroimaging</i> , 1993 , 50, 233-56	2.9	18
294	Early Improvement in Psychosocial Function Predicts Longer-Term Symptomatic Remission in Depressed Patients. <i>PLoS ONE</i> , 2016 , 11, e0167901	3.7	18
293	A pilot study of an electronic, adolescent version of the quick inventory of depressive symptomatology. <i>Journal of Clinical Psychiatry</i> , 2007 , 68, 1436-40	4.6	18
292	Statistical Analysis Plan for Stage 1 EMBARC (Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care) Study. <i>Contemporary Clinical Trials Communications</i> , 2017 , 6, 22-30	1.8	17
291	VitalSign: A Primary Care First (PCP-First) Model for Universal Screening and Measurement-Based Care for Depression. <i>Pharmaceuticals</i> , 2019 , 12,	5.2	17
290	IL-1 β and BDNF are associated with improvement in hypersomnia but not insomnia following exercise in major depressive disorder. <i>Translational Psychiatry</i> , 2015 , 5, e611	8.6	17
289	Early adverse events and attrition in selective serotonin reuptake inhibitor treatment: a suicide assessment methodology study report. <i>Journal of Clinical Psychopharmacology</i> , 2010 , 30, 259-66	1.7	17
288	Assessing physicians' use of treatment algorithms: Project IMPACTS study design and rationale. <i>Contemporary Clinical Trials</i> , 2007 , 28, 192-212	2.3	17
287	Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder. <i>Journal of Clinical Psychopharmacology</i> , 2004 , 24, 497-506	1.7	17
286	Accounting for Dynamic Fluctuations across Time when Examining fMRI Test-Retest Reliability: Analysis of a Reward Paradigm in the EMBARC Study. <i>PLoS ONE</i> , 2015 , 10, e0126326	3.7	17

285	Exercise for mood and anxiety disorders. <i>Journal of Clinical Psychiatry</i> , 2007 , 68, 669-76	4.6	17
284	MAOIs in the Contemporary Treatment of Depression		17
283	A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Adjunctive Pimavanserin in Patients With Major Depressive Disorder and an Inadequate Response to Therapy (CLARITY). <i>Journal of Clinical Psychiatry</i> , 2019 , 80,	4.6	17
282	Reward related ventral striatal activity and differential response to sertraline versus placebo in depressed individuals. <i>Molecular Psychiatry</i> , 2020 , 25, 1526-1536	15.1	17
281	Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features. <i>Journal of Clinical Psychiatry</i> , 2008 , 69, 1928-36	4.6	17
280	Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes: a CO-MED report. <i>Journal of Affective Disorders</i> , 2015 , 174, 157-64	6.6	16
279	Early normalization of Quality of Life predicts later remission in depression: Findings from the CO-MED trial. <i>Journal of Affective Disorders</i> , 2016 , 206, 17-22	6.6	16
278	A Structured Approach to Detecting and Treating Depression in Primary Care: VitalSign6 Project. <i>Annals of Family Medicine</i> , 2019 , 17, 326-335	2.9	16
277	Evaluation of the effects of extended release quetiapine fumarate monotherapy on sleep disturbance in patients with major depressive disorder: a pooled analysis of four randomized acute studies. <i>International Journal of Neuropsychopharmacology</i> , 2013 , 16, 1733-44	5.8	16
276	A psychometric evaluation of the clinician-rated Quick Inventory of Depressive Symptomatology (QIDS-C16) in patients with bipolar disorder. <i>International Journal of Methods in Psychiatric Research</i> , 2009 , 18, 138-46	4.3	16
275	An empirical analysis of cost outcomes of the Texas Medication Algorithm Project. <i>Psychiatric Services</i> , 2006 , 57, 648-59	3.3	16
274	Evaluating and monitoring treatment response in depression using measurement-based assessment and rating scales. <i>Journal of Clinical Psychiatry</i> , 2013 , 74, e14	4.6	16
273	Implementation of the Texas Medication Algorithm Project patient and family education program. <i>Journal of Clinical Psychiatry</i> , 2006 , 67, 1362-72	4.6	16
272	Is C-reactive protein ready for prime time in the selection of antidepressant medications?. <i>Psychoneuroendocrinology</i> , 2017 , 84, 206	5	15
271	Brain regulation of emotional conflict predicts antidepressant treatment response for depression. <i>Nature Human Behaviour</i> , 2019 , 3, 1319-1331	12.8	15
270	Daily activity level improvement with antidepressant medications predicts long-term clinical outcomes in outpatients with major depressive disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2017 , 13, 803-813	3.1	15
269	Brief report: depression and history of suicide attempts in adults with new-onset Type 2 Diabetes. <i>Psychoneuroendocrinology</i> , 2013 , 38, 2810-4	5	15
268	Changes in depressive symptoms and social functioning in the sequenced treatment alternatives to relieve depression study. <i>Journal of Nervous and Mental Disease</i> , 2011 , 199, 807-10	1.8	15

267	Assessing anxious features in depressed outpatients. <i>International Journal of Methods in Psychiatric Research</i> , 2011 , 20, e69-82	4.3	15
266	DATE: Depressed adolescents treated with exercise: Study rationale and design for a pilot study. <i>Mental Health and Physical Activity</i> , 2009 , 2, 76-85	5	15
265	Family history of depression and therapeutic outcome: findings from STAR*D. <i>Journal of Clinical Psychiatry</i> , 2009 , 70, 185-95	4.6	15
264	Resting EEG Measures of Brain Arousal in a Multisite Study of Major Depression. <i>Clinical EEG and Neuroscience</i> , 2019 , 50, 3-12	2.3	15
263	Neuroticism and Individual Differences in Neural Function in Unmedicated Major Depression: Findings from the EMBARC Study. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2017 , 2, 138-148	3.4	14
262	Evaluation of the benefits of exercise on cognition in major depressive disorder. <i>General Hospital Psychiatry</i> , 2017 , 49, 19-25	5.6	14
261	Fatigue in Nondialysis Chronic Kidney Disease: Correlates and Association with Kidney Outcomes. <i>American Journal of Nephrology</i> , 2019 , 50, 37-47	4.6	14
260	Double-blind, proof-of-concept (POC) trial of Low-Field Magnetic Stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD). <i>Brain Stimulation</i> , 2018 , 11, 75-84	5.1	14
259	Rationale and methods for site selection for a trial using a novel intervention to treat stimulant abuse. <i>Contemporary Clinical Trials</i> , 2012 , 33, 29-37	2.3	14
258	Neural correlates of successful response inhibition in unmedicated patients with late-life depression. <i>American Journal of Geriatric Psychiatry</i> , 2012 , 20, 1057-69	6.5	14
257	Indicators of pretreatment suicidal ideation in adults with major depressive disorder. <i>Acta Psychiatrica Scandinavica</i> , 2010 , 121, 480-4	6.5	14
256	The effectiveness of secretin in the management of autism. <i>Expert Opinion on Pharmacotherapy</i> , 2004 , 5, 379-87	4	14
255	Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression. <i>Journal of Affective Disorders</i> , 2020 , 260, 131-139	6.6	14
254	Comparison of technetium-99m-HMPAO and xenon-133 measurements of regional cerebral blood flow by SPECT. <i>Journal of Nuclear Medicine</i> , 1996 , 37, 1735-40	8.9	14
253	Occipital brain perfusion deficits in children with major depressive disorder. <i>Journal of Nuclear Medicine</i> , 2001 , 42, 1059-61	8.9	14
252	Self-rated measure of pain frequency, intensity, and burden: psychometric properties of a new instrument for the assessment of pain. <i>Journal of Psychiatric Research</i> , 2014 , 59, 155-60	5.2	13
251	Effect of concurrent substance use disorder on the effectiveness of single and combination antidepressant medications for the treatment of major depression: an exploratory analysis of a single-blind randomized trial. <i>Depression and Anxiety</i> , 2012 , 29, 111-22	8.4	13
250	The relationship between adverse events during selective serotonin reuptake inhibitor treatment for major depressive disorder and nonremission in the suicide assessment methodology study. <i>Journal of Clinical Psychopharmacology</i> , 2011 , 31, 31-8	1.7	13

249	A comparison of baseline sociodemographic and clinical characteristics between major depressive disorder patients with and without diabetes: a STAR*D report. <i>Journal of Affective Disorders</i> , 2008 , 108, 113-20	6.6	13
248	A SPECT HMPAO study of regional cerebral blood flow in depressed adolescents and normal controls. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1999 , 23, 643-56	5.5	13
247	The development of clinical practice guidelines for the diagnosis and treatment of depression. <i>General Hospital Psychiatry</i> , 1992 , 14, 230-6	5.6	13
246	Comprehensive phenotyping of depression disease trajectory and risk: Rationale and design of Texas Resilience Against Depression study (T-RAD). <i>Journal of Psychiatric Research</i> , 2020 , 122, 22-32	5.2	13
245	Discovery and replication of cerebral blood flow differences in major depressive disorder. <i>Molecular Psychiatry</i> , 2020 , 25, 1500-1510	15.1	13
244	Improving the identification and treatment of depression in low-income primary care clinics: a qualitative study of providers in the VitalSign6 program. <i>International Journal for Quality in Health Care</i> , 2019 , 31, 57-63	1.9	12
243	Body Mass Index as a Moderator of Treatment Response to Ketamine for Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2020 , 40, 287-292	1.7	12
242	Trajectories of suicidal ideation over 6 months among 482 outpatients with bipolar disorder. <i>Journal of Affective Disorders</i> , 2017 , 223, 146-152	6.6	12
241	Determining the primary endpoint for a stimulant abuse trial: lessons learned from STRIDE (CTN 0037). <i>American Journal of Drug and Alcohol Abuse</i> , 2011 , 37, 339-49	3.7	12
240	Telephone-based assessments to minimize missing data in longitudinal depression trials: a project IMPACTS study report. <i>Contemporary Clinical Trials</i> , 2009 , 30, 13-9	2.3	12
239	Family history of completed suicide and characteristics of major depressive disorder: a STAR*D (sequenced treatment alternatives to relieve depression) study. <i>Journal of Affective Disorders</i> , 2008 , 108, 129-34	6.6	12
238	Developing a neuropsychiatric functional brain imaging test. <i>Neurocase</i> , 2008 , 14, 54-8	0.8	12
237	Item Response Analysis of the Inventory of Depressive Symptomatology. <i>Neuropsychiatric Disease and Treatment</i> , 2006 , 2, 557-564	3.1	12
236	Prevalence and impact of obsessive-compulsive symptoms in depression: a STAR*D report. <i>Journal of Clinical Psychiatry</i> , 2015 , 76, 1668-74	4.6	12
235	Use of treatment algorithms for depression. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , 2006 , 8, 291-8		12
234	Affect Following First Exercise Session as a Predictor of Treatment Response in Depression. <i>Journal of Clinical Psychiatry</i> , 2016 , 77, 1036-42	4.6	12
233	Atypical depressive symptoms as a predictor of treatment response to exercise in Major Depressive Disorder. <i>Journal of Affective Disorders</i> , 2016 , 200, 156-8	6.6	12
232	Right patient, right treatment, right time: biosignatures and precision medicine in depression. <i>World Psychiatry</i> , 2016 , 15, 237-238	14.4	12

231	Dissecting the impact of depression on decision-making. <i>Psychological Medicine</i> , 2020 , 50, 1613-1622	6.9	12
230	Consensus guidelines in the treatment of major depressive disorder. <i>Journal of Clinical Psychiatry</i> , 1998 , 59 Suppl 20, 73-84	4.6	12
229	Diurnal mood variation in outpatients with major depressive disorder: implications for DSM-V from an analysis of the Sequenced Treatment Alternatives to Relieve Depression Study data. <i>Journal of Clinical Psychiatry</i> , 2007 , 68, 1339-47	4.6	12
228	Cortical thickness is not associated with current depression in a clinical treatment study. <i>Human Brain Mapping</i> , 2017 , 38, 4370-4385	5.9	11
227	A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don't work well enough?. <i>World Journal of Biological Psychiatry</i> , 2021 , 22, 483-494	3.8	11
226	The Youth Aware of Mental Health Intervention: Impact on Help Seeking, Mental Health Knowledge, and Stigma in U.S. Adolescents. <i>Journal of Adolescent Health</i> , 2020 , 67, 101-107	5.8	11
225	Psychometric properties of the concise health risk tracking (CHRT) in adolescents with suicidality. <i>Journal of Affective Disorders</i> , 2018 , 235, 45-51	6.6	11
224	Culturally adapted depression education and engagement in treatment among Hispanics in primary care: outcomes from a pilot feasibility study. <i>BMC Family Practice</i> , 2019 , 20, 140	2.6	11
223	Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder. <i>International Journal of Neuropsychopharmacology</i> , 2017 , 20, 613-618	5.8	11
222	Stimulant Reduction Intervention using Dosed Exercise (STRIDE) - Description of the Exercise Intervention and Behavioral Program to Ensure Adherence. <i>Mental Health and Physical Activity</i> , 2012 , 5, 175-182	5	11
221	Clinically Relevant Findings from STAR*D. <i>Psychiatric Annals</i> , 2008 , 38,	0.5	11
220	Dysfunctional adaptive immune response in adolescents and young adults with suicide behavior. <i>Psychoneuroendocrinology</i> , 2020 , 111, 104487	5	11
219	Depression Screening and Education: Options to Reduce Barriers to Treatment (DESEO): protocol for an educational intervention study. <i>BMC Health Services Research</i> , 2016 , 16, 322	2.9	11
218	Comorbidities and race/ethnicity among adults with stimulant use disorders in residential treatment. <i>Journal of Ethnicity in Substance Abuse</i> , 2015 , 14, 79-95	1.1	10
217	Utilizing a Two-stage Design to Investigate the Safety and Potential Efficacy of Monthly Naltrexone Plus Once-daily Bupropion as a Treatment for Methamphetamine Use Disorder. <i>Journal of Addiction Medicine</i> , 2016 , 10, 236-43	3.8	10
216	A tool to predict suicidal ideation and behavior in bipolar disorder: The Concise Health Risk Tracking Self-Report. <i>Journal of Affective Disorders</i> , 2016 , 192, 212-8	6.6	10
215	Childhood depression subscales using repeated sessions on Children's Depression Rating Scale - revised (CDRS-R) scores. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2014 , 24, 318-24	2.9	10
214	Research staff training in a multisite randomized clinical trial: Methods and recommendations from the Stimulant Reduction Intervention using Dosed Exercise (STRIDE) trial. <i>Addiction Research and Theory</i> , 2014 , 22, 407-415	2.6	10

213	Power of automated algorithms for combining time-line follow-back and urine drug screening test results in stimulant-abuse clinical trials. <i>American Journal of Drug and Alcohol Abuse</i> , 2011 , 37, 350-7	3.7	10
212	A review of quetiapine in combination with antidepressant therapy in patients with depression. <i>Neuropsychiatric Disease and Treatment</i> , 2007 , 3, 855-67	3.1	10
211	Quantitative EEG amplitude across REM sleep periods in depression: preliminary report. <i>Journal of Psychiatry and Neuroscience</i> , 2002 , 27, 40-6	4.5	10
210	Are depressed outpatients with and without a family history of substance use disorder different? A baseline analysis of the STAR*D cohort. <i>Journal of Clinical Psychiatry</i> , 2007 , 68, 1931-8	4.6	10
209	Frontal theta and posterior alpha in resting EEG: A critical examination of convergent and discriminant validity. <i>Psychophysiology</i> , 2020 , 57, e13483	4.1	10
208	Effects of depression, metabolic syndrome, and cardiorespiratory fitness on mortality: results from the Cooper Center Longitudinal Study. <i>Psychological Medicine</i> , 2017 , 47, 2414-2420	6.9	9
207	Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder. <i>Neuropsychopharmacology</i> , 2019 , 44, 2268-2276	8.7	9
206	A Health Education Intervention as the Control Condition in the CTN-0037 STRIDE multi-site exercise trial: Rationale and Description. <i>Mental Health and Physical Activity</i> , 2014 , 7, 37-41	5	9
205	Depressive Symptoms and Associated Clinical Characteristics in Outpatients Seeking Community-Based Treatment for Alcohol and Drug Problems. <i>Substance Abuse</i> , 2015 , 36, 297-303	3.8	9
204	The impact of nonclinical factors on care use for patients with depression: a STAR*D report. <i>CNS Neuroscience and Therapeutics</i> , 2009 , 15, 320-32	6.8	9
203	Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report. <i>Focus (American Psychiatric Publishing)</i> , 2008 , 6, 128-142	1.1	9
202	Reductions in stress and depressive symptoms in mothers of substance-exposed infants, participating in a psychosocial program. <i>Maternal and Child Health Journal</i> , 2004 , 8, 127-36	2.4	9
201	Clinicians' adherence to an algorithm for pharmacotherapy of depression in the Texas public mental health sector. <i>Psychiatric Services</i> , 2004 , 55, 703-5	3.3	9
200	Growth hormone response to baclofen: a comparison of 10-mg and 20-mg doses in healthy men. <i>Psychiatry Research</i> , 1996 , 60, 41-7	9.9	9
199	Managing depressive disorders in patients with epilepsy. <i>Psychiatry</i> , 2007 , 4, 26-34		9
198	Analysis of suicidality in pooled data from 2 double-blind, placebo-controlled aripiprazole adjunctive therapy trials in major depressive disorder. <i>Journal of Clinical Psychiatry</i> , 2011 , 72, 548-55	4.6	9
197	Efficacy of a Behavioral Activation Teletherapy Intervention to Treat Depression and Anxiety in Primary Care VitalSign6 Program. <i>primary care companion for CNS disorders, The</i> , 2017 , 19,	1.2	9
196	Developing treatment algorithms for unipolar depression in Cyberspace: International Psychopharmacology Algorithm Project (IPAP). <i>Psychopharmacology Bulletin</i> , 1998 , 34, 355-9	0.9	9

195	The Concise Health Risk Tracking-Self Report: Psychometrics within a placebo-controlled antidepressant trial among depressed outpatients. <i>Journal of Psychopharmacology</i> , 2019 , 33, 185-193	4.6	8
194	Cerebral Blood Perfusion Predicts Response to Sertraline versus Placebo for Major Depressive Disorder in the EMBARC Trial. <i>EclinicalMedicine</i> , 2019 , 10, 32-41	11.3	8
193	Pretreatment Reward Sensitivity and Frontostriatal Resting-State Functional Connectivity Are Associated With Response to Bupropion After Sertraline Nonresponse. <i>Biological Psychiatry</i> , 2020 , 88, 657-667	7.9	8
192	Do baseline sub-threshold hypomanic symptoms affect acute-phase antidepressant outcome in outpatients with major depressive disorder? Preliminary findings from the randomized CO-MED trial. <i>Neuropsychopharmacology</i> , 2018 , 43, 2197-2203	8.7	8
191	Role of metabolic dysfunction in treatment resistance of major depressive disorder. <i>Neuropsychiatry</i> , 2011 , 1, 441-455	1.8	8
190	Effectiveness Study of Venlafaxine-XR Combined with Aripiprazole for Chronic or Recurrent Major Depressive Disorder. <i>Australian and New Zealand Journal of Psychiatry</i> , 2009 , 43, 956-967	2.6	8
189	Factors associated with concomitant psychotropic drug use in the treatment of major depression: a STAR*D Report. <i>CNS Spectrums</i> , 2009 , 14, 487-98	1.8	8
188	Remission and recovery in depression treatment. <i>Drug Development Research</i> , 2005 , 65, 335-343	5.1	8
187	Computerizing medication algorithms and decision support systems for major psychiatric disorders. <i>Journal of Psychiatric Practice</i> , 2000 , 6, 237-46	1.3	8
186	Remission with venlafaxine extended release or selective serotonin reuptake inhibitors in depressed patients: a randomized, open-label study. <i>primary care companion for CNS disorders, The</i> , 2011 , 13,	1.2	8
185	Demographic and clinical characteristics of current comorbid psychiatric disorders in a randomized clinical trial for adults with stimulant use disorders. <i>Psychiatry Research</i> , 2016 , 246, 136-141	9.9	8
184	Performance of depression rating scales in patients with chronic kidney disease: an item response theory-based analysis. <i>General Hospital Psychiatry</i> , 2016 , 42, 60-6	5.6	8
183	Focusing on insomnia symptoms to better understand depression: A STAR*D report. <i>Journal of Affective Disorders</i> , 2020 , 260, 183-186	6.6	8
182	Algorithm for the treatment of chronic depression. <i>Journal of Clinical Psychiatry</i> , 2001 , 62 Suppl 6, 22-9	4.6	8
181	Measurement, Education and Tracking in Integrated Care (METRIC): use of a culturally adapted education tool versus standard education to increase engagement in depression treatment among Hispanic patients: study protocol for a randomized control trial. <i>Trials</i> , 2017 , 18, 363	2.8	7
180	Characterizing anxiety subtypes and the relationship to behavioral phenotyping in major depression: Results from the EMBARC study. <i>Journal of Psychiatric Research</i> , 2018 , 102, 207-215	5.2	7
179	Pilot investigation into the sickness response to influenza vaccination in adults: Effect of depression and anxiety. <i>General Hospital Psychiatry</i> , 2017 , 48, 56-61	5.6	7
178	How Commonly Used Inclusion and Exclusion Criteria in Antidepressant Registration Trials Affect Study Enrollment. <i>Journal of Psychiatric Practice</i> , 2015 , 21, 267-74	1.3	7

177	Feasible evidence-based strategies to manage depression in primary care. <i>Current Psychiatry Reports</i> , 2012 , 14, 370-5	9.1	7
176	Treatment-resistant depression: new therapies on the horizon. <i>Annals of Clinical Psychiatry</i> , 2003 , 15, 59-70	1.4	7
175	Rationale for Using Exercise in the Treatment of Stimulant Use Disorders 2012 , 6,		7
174	Crisis of confidence: antidepressant risk versus benefit. <i>Journal of Clinical Psychiatry</i> , 2011 , 72, e11	4.6	7
173	Predicting Response to the Antidepressant Bupropion using Pretreatment fMRI. <i>Lecture Notes in Computer Science</i> , 2019 , 11843, 53-62	0.9	7
172	Harmonized Outcome Measures for Use in Depression Patient Registries and Clinical Practice. <i>Annals of Internal Medicine</i> , 2020 , 172, 803-809	8	7
171	Association between irritability and suicidal ideation in three clinical trials of adults with major depressive disorder. <i>Neuropsychopharmacology</i> , 2020 , 45, 2147-2154	8.7	7
170	Higher S100B Levels Predict Persistently Elevated Anhedonia with Escitalopram Monotherapy Versus Antidepressant Combinations: Findings from CO-MED Trial. <i>Pharmaceuticals</i> , 2019 , 12,	5.2	7
169	Toward a very brief quality of life enjoyment and Satisfaction Questionnaire. <i>Journal of Affective Disorders</i> , 2019 , 242, 87-95	6.6	7
168	Feasibility and Acceptability of the Youth Aware of Mental Health (YAM) Intervention in US Adolescents. <i>Archives of Suicide Research</i> , 2020 , 24, 269-284	2.3	7
167	Racial and ethnic differences in treatment outcomes among adults with stimulant use disorders after a dosed exercise intervention. <i>Journal of Ethnicity in Substance Abuse</i> , 2017 , 16, 495-510	1.1	6
166	Toward a very brief self-report to assess the core symptoms of depression (VQIDS-SR). <i>Acta Psychiatrica Scandinavica</i> , 2017 , 135, 548-553	6.5	6
165	Men and women from the STRIDE clinical trial: An assessment of stimulant abstinence symptom severity at residential treatment entry. <i>American Journal on Addictions</i> , 2015 , 24, 336-40	3.7	6
164	A psychometric evaluation of the Concise Health Risk Tracking Self-Report (CHRT-SR)- a measure of suicidality-in patients with stimulant use disorder. <i>Journal of Psychiatric Research</i> , 2018 , 102, 65-71	5.2	6
163	The Promoting Activity in Cancer Survivors (PACES) trial: a multiphase optimization of strategy approach to increasing physical activity in breast cancer survivors. <i>BMC Cancer</i> , 2018 , 18, 744	4.8	6
162	Risk for Partner Victimization and Marital Dissatisfaction Among Chronically Depressed Patients. <i>Journal of Family Violence</i> , 2012 , 27, 75-85	3	6
161	An ounce of prevention: A pre-randomization protocol to improve retention in substance use disorder clinical trials. <i>Addictive Behaviors</i> , 2017 , 64, 137-142	4.2	6
160	Measurement-Based Care in the Treatment of Clinical Depression. <i>Focus (American Psychiatric Publishing)</i> , 2012 , 10, 428-433	1.1	6

159	Quetiapine XR monotherapy in major depressive disorder: a pooled analysis to assess the influence of baseline severity on efficacy. <i>International Clinical Psychopharmacology</i> , 2013 , 28, 113-20	2.2	6
158	The psychopharmacological treatment of nonmajor mood disorders. <i>Modern Problems of Pharmacopsychiatry</i> , 1997 , 25, 146-66		6
157	Quality improvement methods as applied to a multicenter effectiveness trial--STAR*D. <i>Contemporary Clinical Trials</i> , 2005 , 26, 95-112	2.3	6
156	A quality improvement process for implementing the Texas algorithm for schizophrenia in Ohio. <i>Psychiatric Services</i> , 2003 , 54, 1646-9	3.3	6
155	Methods of testing feasibility for sequenced treatment alternatives to relieve depression (STAR*D). <i>Journal of Psychiatric Research</i> , 2004 , 38, 241-8	5.2	6
154	Intermediate outcome of medical patients after intensive care. <i>Anaesthesia</i> , 2001 , 56, 841-6	6.6	6
153	A comparison of alternative assessments of depressive symptom severity: a pilot study. <i>Psychiatry Research</i> , 2000 , 95, 55-65	9.9	6
152	What to Expect When Switching to a Second Antidepressant Medication Following an Ineffective Initial SSRI: A Report From the Randomized Clinical STAR*D Study. <i>Journal of Clinical Psychiatry</i> , 2020 , 81,	4.6	6
151	A Systematic Review and Meta-Analysis of Depression and Protein-Energy Wasting in Kidney Disease. <i>Kidney International Reports</i> , 2020 , 5, 318-330	4.1	6
150	Childhood maltreatment and impact on clinical features of major depression in adults. <i>Psychiatry Research</i> , 2020 , 293, 113412	9.9	6
149	Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial. <i>American Journal of Psychiatry</i> , 2021 , 178, 437-446	11.9	6
148	Anxiety and anhedonia in depression: Associations with neuroticism and cognitive control. <i>Journal of Affective Disorders</i> , 2019 , 245, 1070-1078	6.6	6
147	Pharmacogenomics and Biomarkers of Depression. <i>Handbook of Experimental Pharmacology</i> , 2019 , 250, 101-113	3.2	6
146	VitalSign: Screening, Diagnosis, and Treatment of Depression for Adolescents Presenting to Pediatric Primary and Specialty Care Settings. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2019 , 58, 632-635	7.2	5
145	Positive and negative valence systems in major depression have distinct clinical features, response to antidepressants, and relationships with immunomarkers. <i>Depression and Anxiety</i> , 2020 , 37, 771-783	8.4	5
144	Improvements in irritability with sertraline versus placebo: Findings from the EMBARC study. <i>Journal of Affective Disorders</i> , 2020 , 275, 44-47	6.6	5
143	A pilot program for implementing mental health screening, assessment, and navigation in a community-based cancer center. <i>Psycho-Oncology</i> , 2018 , 27, 683-686	3.9	5
142	Prognostic Utility of a Self-Reported Depression Questionnaire versus Clinician-Based Assessment on Renal Outcomes. <i>American Journal of Nephrology</i> , 2016 , 44, 234-44	4.6	5

141	Evaluation of newer treatment interventions for psychotic depression. <i>Current Psychiatry Reports</i> , 2000 , 2, 305-9	9.1	5
140	Biomarkers and the future of treatment for depression. <i>Cerebrum: the Dana Forum on Brain Science</i> , 2012 , 2012, 6	0	5
139	Death by Insulin: Management of Self-Harm and Suicide in Diabetes Management. <i>Current Diabetes Reviews</i> , 2017 , 13, 251-262	2.7	5
138	Research priorities for expanding access to methadone treatment for opioid use disorder in the United States: A National Institute on Drug Abuse Center for Clinical Trials Network Task Force report. <i>Substance Abuse</i> , 2021 , 42, 245-254	3.8	5
137	Dysregulation of mitochondrial dynamics, mitophagy and apoptosis in major depressive disorder: Does inflammation play a role?. <i>Molecular Psychiatry</i> , 2021 ,	15.1	5
136	Depressive Disorders in HIV/AIDS: A Clinically Focused Narrative Review. <i>Harvard Review of Psychiatry</i> , 2020 , 28, 146-158	4.1	5
135	Adiponectin Moderates Antidepressant Treatment Outcome in the Combining Medications to Enhance Depression Outcomes Randomized Clinical Trial. <i>Personalized Medicine in Psychiatry</i> , 2018 , 9-10, 1-7	1.1	5
134	Anger attacks are associated with persistently elevated irritability in MDD: findings from the EMBARC study. <i>Psychological Medicine</i> , 2020 , 1-9	6.9	4
133	A Complier Average Causal Effect Analysis of the Stimulant Reduction Intervention using Dosed Exercise Study. <i>Contemporary Clinical Trials Communications</i> , 2018 , 10, 1-8	1.8	4
132	Effects of heart disease on depression treatment: results from the COMED study. <i>General Hospital Psychiatry</i> , 2012 , 34, 24-34	5.6	4
131	Sustaining practice change one year after completion of the national depression management leadership initiative. <i>Psychiatric Services</i> , 2013 , 64, 703-6	3.3	4
130	Insured and non-insured depressed outpatients: how do they compare?. <i>Annals of Clinical Psychiatry</i> , 2007 , 19, 73-82	1.4	4
129	Dr. Trivedi and Colleagues Reply. <i>American Journal of Psychiatry</i> , 2006 , 163, 1293-1294	11.9	4
128	Polysomnogram in major depressive and obsessive-compulsive disorders: A preliminary study. <i>Depression</i> , 1994 , 2, 297-302		4
127	Assessing rates and predictors of tachyphylaxis during the prevention of recurrent episodes of depression with venlafaxine ER for two years (PREVENT) study. <i>Psychopharmacology Bulletin</i> , 2009 , 42, 5-20	0.9	4
126	The Status of Evidence-Based Guidelines and Algorithms in the Treatment of Depression. <i>Psychiatric Annals</i> , 2002 , 32, 658-663	0.5	4
125	Treating depression complicated by comorbid medical illness or anxiety. <i>Journal of Clinical Psychiatry</i> , 2007 , 68, e01	4.6	4
124	Major Depressive Disorder in Primary Care: Strategies for Identification. <i>Journal of Clinical Psychiatry</i> , 2020 , 81,	4.6	4

123	Harmonization of cortical thickness measurements across scanners and sites		4
122	Psychometric Properties of the Concise Associated Symptom Tracking Scale and Validation of Clinical Utility in the EMBARC Study. <i>Psychiatric Research and Clinical Practice</i> , 2020 , 2, 10-18	2.7	4
121	Depression Screening and Measurement-Based Care in Primary Care. <i>Journal of Primary Care and Community Health</i> , 2020 , 11, 2150132720931261	2.1	4
120	Clinically meaningful changes on depressive symptom measures and patient-reported outcomes in patients with treatment-resistant depression. <i>Acta Psychiatrica Scandinavica</i> , 2021 , 143, 253-263	6.5	4
119	The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind study. <i>European Neuropsychopharmacology</i> , 2021 , 49, 122-132	1.2	4
118	Prediction of short-term antidepressant response using probabilistic graphical models with replication across multiple drugs and treatment settings. <i>Neuropsychopharmacology</i> , 2021 , 46, 1272-1282	8.7	4
117	Clinical significance of monitoring early symptom change to predict outcome. <i>Journal of Clinical Psychiatry</i> , 2001 , 62 Suppl 4, 27-33; discussion 37-40	4.6	4
116	Using treatment algorithms for the effective management of treatment-resistant depression. <i>Journal of Clinical Psychiatry</i> , 2001 , 62 Suppl 18, 25-9	4.6	4
115	Sensitizing clinicians and patients to the social and functional aspects of remission. <i>Journal of Clinical Psychiatry</i> , 2001 , 62 Suppl 19, 32-5	4.6	4
114	On the invariance of the Stimulant Craving Questionnaire (STCQ) across cocaine and methamphetamine users. <i>Addictive Behaviors</i> , 2015 , 42, 144-7	4.2	3
113	Effect of adjunctive pimavanserin on suicidal ideation in patients with major depression: Analysis of the CLARITY study. <i>Journal of Affective Disorders</i> , 2020 , 277, 478-485	6.6	3
112	Depression and the Effect of Sertraline on Inflammatory Biomarkers in Patients with Nondialysis CKD.. <i>Kidney360</i> , 2020 , 1, 436-446	1.8	3
111	Improvement of sexual functioning during treatment of MDD with adjunctive pimavanserin: A secondary analysis. <i>Depression and Anxiety</i> , 2020 , 37, 485-495	8.4	3
110	Baseline medical comorbidities in adults randomized in the STRIDE trial for psychostimulant use disorders. <i>American Journal on Addictions</i> , 2016 , 25, 215-20	3.7	3
109	Accurately identifying patients who are excellent candidates or unsuitable for a medication: a novel approach. <i>Neuropsychiatric Disease and Treatment</i> , 2017 , 13, 3001-3010	3.1	3
108	Do geographic regions with higher suicide rates also have higher rates of nonfatal intentional self-harm?. <i>Suicide and Life-Threatening Behavior</i> , 2008 , 38, 637-49	3.9	3
107	Datapoints: rates of nonfatal intentional self-harm in nine states, 2001. <i>Psychiatric Services</i> , 2006 , 57, 313	3.3	3
106	Anatomically-Informed Data Augmentation for Functional MRI with Applications to Deep Learning. <i>Proceedings of SPIE</i> , 2020 , 11313,	1.7	3

105	Challenges and algorithm-guided treatment in major depressive disorder. <i>Journal of Clinical Psychiatry</i> , 2011 , 72, e14	4.6	3
104	Psychometrics of the Self-Report Concise Associated Symptoms Tracking Scale (CAST-SR): Results From the STRIDE (CTN-0037) Study. <i>Journal of Clinical Psychiatry</i> , 2018 , 79,	4.6	3
103	Effect of Adjunctive Pimavanserin on Sleep/Wakefulness in Patients With Major Depressive Disorder: Secondary Analysis From CLARITY. <i>Journal of Clinical Psychiatry</i> , 2020 , 82,	4.6	3
102	Inflammation and Response to Sertraline Treatment in Patients With CKD and Major Depression. <i>American Journal of Kidney Diseases</i> , 2020 , 75, 457-460	7.4	3
101	Kynurenine pathway metabolites selectively associate with impaired associative memory function in depression. <i>Brain, Behavior, & Immunity - Health</i> , 2020 , 8, 100126	5.1	3
100	Effect of pimavanserin on anxious depression in patients with major depression and an inadequate response to previous therapy: secondary analysis of the clarity study. <i>International Clinical Psychopharmacology</i> , 2020 , 35, 313-321	2.2	3
99	School Personnel and Parents' Concerns Related to COVID-19 Pandemic: Impact Related to Schools. <i>School Psychology Review</i> , 1-11	1.6	3
98	Clinically Significant Changes in the 17- and 6-Item Hamilton Rating Scales for Depression: A STAR*D Report. <i>Neuropsychiatric Disease and Treatment</i> , 2021 , 17, 2333-2345	3.1	3
97	Neuroimaging correlates and predictors of response to repeated-dose intravenous ketamine in PTSD: preliminary evidence. <i>Neuropsychopharmacology</i> , 2021 , 46, 2266-2277	8.7	3
96	Association of anger attacks with suicidal ideation in adults with major depressive disorder: Findings from the EMBARC study. <i>Depression and Anxiety</i> , 2021 , 38, 57-66	8.4	3
95	Profiles of depression in a treatment-seeking Hispanic population: Psychometric properties of the Patient Health Questionnaire-9. <i>International Journal of Methods in Psychiatric Research</i> , 2021 , 30, e18514-3	4.3	3
94	Patterns of Pretreatment Reward Task Brain Activation Predict Individual Antidepressant Response: Key Results From the EMBARC Randomized Clinical Trial.. <i>Biological Psychiatry</i> , 2021 ,	7.9	3
93	Voice response system to measure healthcare costs: a STAR*D report. <i>American Journal of Managed Care</i> , 2009 , 15, 153-62	2.1	3
92	Opioid addiction screening tools for patients with chronic noncancer pain. <i>Texas Medicine</i> , 2015 , 111, 61-5	1	3
91	Acute and long-term cannabis use among stimulant users: Results from CTN-0037 Stimulant Reduction Intervention using Dosed Exercise (STRIDE) Randomized Control Trial. <i>Drug and Alcohol Dependence</i> , 2019 , 200, 139-144	4.9	2
90	When Discontinuing SSRI Antidepressants Is a Challenge: A Response to Letters to the Editor. <i>American Journal of Psychiatry</i> , 2019 , 176, 488-489	11.9	2
89	Examining raphe-amygdala structural connectivity as a biological predictor of SSRI response. <i>Journal of Affective Disorders</i> , 2019 , 256, 8-16	6.6	2
88	Prediction of Acute-Phase Treatment Outcomes by Adding a Single-Item Measure of Activity Impairment to Symptom Measurement: Development and Validation of an Interactive Calculator from the STAR*D and CO-MED Trials. <i>International Journal of Neuropsychopharmacology</i> , 2019 , 22, 339-348	5.8	2

87	Predicting future suicidal events in adolescents using the Concise Health Risk Tracking Self-Report (CHRT-SR). <i>Journal of Psychiatric Research</i> , 2020 , 126, 19-25	5.2	2
86	Temporal sustainability of guideline based door-to-needle times for intravenous thrombolysis for acute ischemic stroke. <i>Journal of Clinical Neuroscience</i> , 2020 , 74, 164-167	2.2	2
85	Experimental Therapies for Treatment-Resistant Depression: "How do you decide when to go to an unproven or experimental therapy with patients that are treatment-resistant depression?". <i>Focus (American Psychiatric Publishing)</i> , 2018 , 16, 279-284	1.1	2
84	Symptoms of Major Depressive Disorder Scale: Performance of a Novel Patient-Reported Symptom Measure. <i>Value in Health</i> , 2019 , 22, 906-915	3.3	2
83	Psychosocial relationship status and quality as predictors of exercise intervention adherence and substance use outcomes: Results from the STRIDE (CTN-0037) study. <i>Psychiatry Research</i> , 2017 , 254, 332-339	9.9	2
82	Response to Blier Letter. <i>American Journal of Psychiatry</i> , 2012 , 169, 95-96	11.9	2
81	Screening for depression in a diabetic outpatient population. <i>International Journal of Psychiatry in Clinical Practice</i> , 2007 , 11, 268-72	2.4	2
80	Use of Decision Support Tools for Treatment Algorithms. <i>CNS Spectrums</i> , 2007 , 12, 9-16	1.8	2
79	Treatment with low doses of tranylcypromine resulted in a disappointing remission rate. <i>American Journal of Psychiatry</i> , 2007 , 164, 524; author reply 524	11.9	2
78	Occlusion of a tracheostomy tube after misinsertion. <i>Anaesthesia</i> , 2006 , 61, 407-8; discussion 408	6.6	2
77	How Can Measurement-Based Care Help Improve Treatment Outcomes for Major Depressive Disorder in Primary Care?. <i>Journal of Clinical Psychiatry</i> , 2020 , 81,	4.6	2
76	Tackling partial response to depression treatment. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , 2009 , 11, 155-62		2
75	Multi-omics driven predictions of response to acute phase combination antidepressant therapy: a machine learning approach with cross-trial replication. <i>Translational Psychiatry</i> , 2021 , 11, 513	8.6	2
74	Quality of life after response to acute-phase cognitive therapy for recurrent depression. <i>Journal of Affective Disorders</i> , 2021 , 278, 218-225	6.6	2
73	If there were an effective pharmacotherapy for cocaine use disorder, what would it do?. <i>Addiction</i> , 2021 , 116, 714-715	4.6	2
72	Creation of an algorithm for clinical decision support for treatment of opioid use disorder with buprenorphine in primary care. <i>Addiction Science & Clinical Practice</i> , 2021 , 16, 12	4.1	2
71	Sex-specific differences in the association between body mass index and brain aging in young adults: Findings from the human connectome project. <i>Psychoneuroendocrinology</i> , 2021 , 124, 105059	5	2
70	Functional neuroanatomy of obsessive-compulsive disorder. <i>Journal of Clinical Psychiatry</i> , 1996 , 57 Suppl 8, 26-35; discussion 36	4.6	2

69	Using treatment algorithms to bring patients to remission. <i>Journal of Clinical Psychiatry</i> , 2003 , 64 Suppl 2, 8-13	4.6	2
68	Remission of depression and the Texas Medication Algorithm Project. <i>Managed Care Interface</i> , 2003 , Suppl B, 9-13		2
67	Understanding the Impact of Treatment on the Dimensions of Childhood Depression. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2017 , 27, 160-166	2.9	1
66	The Stimulant Selective Severity Assessment: A replication and exploratory extension of the Cocaine Selective Severity Assessment. <i>Substance Use and Misuse</i> , 2019 , 54, 351-361	2.2	1
65	50 Adjunctive Buprenorphine/Samidorphan Combination in Patients with Major Depressive Disorder: Phase 3 Long-term Extension Study Results. <i>CNS Spectrums</i> , 2019 , 24, 203-204	1.8	1
64	The Adolescent Resilience Questionnaire: Validation of a Shortened Version in U.S. Youths. <i>Frontiers in Psychology</i> , 2020 , 11, 606373	3.4	1
63	Cardiorespiratory fitness and body composition of stimulant users: A baseline analysis of the STRIDE cohort. <i>Journal of Substance Abuse Treatment</i> , 2017 , 78, 74-79	4.2	1
62	Optimization of Treatment Algorithms for Clinical Depression: Glutamate Antagonists and Transcranial Magnetic Stimulation as Case Examples. <i>Focus (American Psychiatric Publishing)</i> , 2014 , 12, 146-151	1.1	1
61	Combining Medications to Enhance Depression Outcomes (CO-MED): Acute and Long-Term Outcomes of a Single-Blind Randomized Study. <i>Focus (American Psychiatric Publishing)</i> , 2012 , 10, 492-505 ^{1.1}		1
60	Anticipated Benefits of Care (ABC): psychometrics and predictive value in psychiatric disorders. <i>Psychological Medicine</i> , 2010 , 40, 955-65	6.9	1
59	Cognitive Therapy Augmentation versus CT Switch Treatment: A STAR*D Report. <i>International Journal of Cognitive Therapy</i> , 2009 , 2, 66-87	1.4	1
58	Release bias in accessing medical records in clinical trials: a STAR*D report. <i>International Journal of Methods in Psychiatric Research</i> , 2009 , 18, 147-58	4.3	1
57	Fibroblast growth factor 21 (FGF21) is increased in MDD and interacts with body mass index (BMI) to affect depression trajectory.. <i>Translational Psychiatry</i> , 2022 , 12, 16	8.6	1
56	Implementing mental health screening, assessment, and navigation program in a community-based survivorship program.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 36-36	2.2	1
55	Inadequate Response to Antidepressant Treatment in Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2020 , 81,	4.6	1
54	Central Disorders of Hypersomnolence in Children and Adults: A Comparative Study from South India. <i>Annals of Indian Academy of Neurology</i> , 2019 , 22, 442-446	0.9	1
53	Using measurement-based care with patient involvement to improve outcomes in depression. <i>primary care companion for CNS disorders</i> , 2013 , 15,	1.2	1
52	Cross-Sectional Associations Among Symptoms of Pain, Irritability, and Depression and How These Symptoms Relate to Social Functioning and Quality of Life: Findings From the EMBARC and STRIDE Studies and the VitalSign6 Project. <i>Journal of Clinical Psychiatry</i> , 2021 , 82,	4.6	1

51	Suicidal Ideation and Depression Among Adolescent and Young Adult Cancer Patients. <i>Journal of Adolescent and Young Adult Oncology</i> , 2021 , 10, 549-554	2.2	1
50	The Treatment with Exercise Augmentation for Depression (TREAD) study96-108		1
49	Biomarker-Based Treatment Selection: A Precision Medicine Approach for Depression 2019 , 331-340		1
48	The Concise Health Risk Tracking Self-Report (CHRT-SR) assessment of suicidality in depressed outpatients: A psychometric evaluation. <i>Depression and Anxiety</i> , 2019 , 36, 313-320	8.4	1
47	Dorsolateral Prefrontal Cortex and Subcallosal Cingulate Connectivity Show Preferential Antidepressant Response in Major Depressive Disorder. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2021 , 6, 20-28	3.4	1
46	Reply to: EEG-based model and antidepressant response. <i>Nature Biotechnology</i> , 2021 , 39, 28-29	44.5	1
45	Impact of childhood maltreatment on outcomes of antidepressant medication in chronic and/or recurrent depression. <i>Journal of Affective Disorders</i> , 2021 , 291, 39-45	6.6	1
44	Dysfunction of default mode network is associated with active suicidal ideation in youths and young adults with depression: Findings from the T-RAD study. <i>Journal of Psychiatric Research</i> , 2021 , 142, 258-262	5.2	1
43	Socioeconomic Predictors of Treatment Outcomes Among Adults With Major Depressive Disorder.. <i>Psychiatric Services</i> , 2022 , appi202100559	3.3	1
42	Spontaneous fetal loss in women with epilepsy: prospective data from pregnancy registry in India. <i>Epilepsy Research</i> , 2018 , 146, 50-53	3	0
41	The Effect of Antidepressant Therapy on Blood Pressure and Heart Rate Variability. <i>Psychopharm Review: Timely Reports in Psychopharmacology and Device-based Therapies</i> , 2013 , 48, 1-7		0
40	A primary care first (PCP-first) model to screen and treat depression: A VitalSign report from a second cohort of 32,106 patients. <i>General Hospital Psychiatry</i> , 2021 , 74, 1-8	5.6	0
39	Dural venous sinus thrombosis following intravitreal bevacizumab. <i>Neurology India</i> , 2017 , 65, 166-167	0.7	0
38	The effectiveness of enhanced evidence-based care for depressive disorders: a meta-analysis of randomized controlled trials. <i>Translational Psychiatry</i> , 2021 , 11, 531	8.6	0
37	Treating partial responders to antidepressant treatment. <i>Journal of Clinical Psychiatry</i> , 2009 , 70, e31	4.6	0
36	Gender and racial/ethnic differences in physiologic responses in the Stimulant Reduction Intervention using Dosed Exercise Study. <i>Addictive Behaviors</i> , 2020 , 110, 106546	4.2	0
35	Exploration of baseline and early changes in neurocognitive characteristics as predictors of treatment response to bupropion, sertraline, and placebo in the EMBARC clinical trial. <i>Psychological Medicine</i> , 2020 , 1-9	6.9	0
34	Electronic Mental Health Screening in a Pediatric Heart Failure and Transplant Clinic. <i>Journal of Clinical Psychology in Medical Settings</i> , 2021 , 28, 815-825	2	0

33	Psychometric Evaluation of the Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire in a General Youth Population. <i>Child Psychiatry and Human Development</i> , 2021 , 1	3.3	o
32	Differential response to SSRI versus Placebo and distinct neural signatures among data-driven subgroups of patients with major depressive disorder. <i>Journal of Affective Disorders</i> , 2021 , 282, 602-610	6.6	o
31	Psychopharmacology and Experimental Therapeutics for Bipolar Depression. <i>Focus (American Psychiatric Publishing)</i> , 2019 , 17, 232-237	1.1	o
30	Identifying and responding to trial implementation challenges during multisite clinical trials. <i>Journal of Substance Abuse Treatment</i> , 2020 , 112S, 63-72	4.2	o
29	The effect of esketamine in patients with treatment-resistant depression with and without comorbid anxiety symptoms or disorder. <i>Depression and Anxiety</i> , 2021 , 38, 1120-1130	8.4	o
28	Smoking status links habenular volume to glycated hemoglobin: Findings from the Human Connectome Project-Young Adult. <i>Psychoneuroendocrinology</i> , 2021 , 131, 105321	5	o
27	Irritability as an independent predictor of concurrent and future suicidal ideation in adults with stimulant use disorder: Findings from the STRIDE study. <i>Journal of Affective Disorders</i> , 2021 , 292, 108-113	6.6	o
26	Impact of the COVID-19 pandemic on adults with current and prior depression: initial findings from the longitudinal Texas RAD study. <i>Journal of Affective Disorders</i> , 2021 , 294, 103-108	6.6	o
25	Comparison of inflammatory markers as moderators of depression outcomes: A CO-MED study. <i>Journal of Affective Disorders</i> , 2021 , 295, 1066-1071	6.6	o
24	Psychometric and Clinical Evaluation of the Clinician (VQIDS-C) and Self-Report (VQIDS-SR) Versions of the Very Quick Inventory of Depressive Symptoms.. <i>Neuropsychiatric Disease and Treatment</i> , 2022 , 18, 289-302	3.1	o
23	Pitfalls and Recommended Strategies and Metrics for Suppressing Motion Artifacts in Functional MRI.. <i>Neuroinformatics</i> , 2022 , 1	3.2	o
22	Neural substrates of emotional conflict with anxiety in major depressive disorder: Findings from the Establishing Moderators and biosignatures of Antidepressant Response in Clinical Care (EMBARC) randomized controlled trial.. <i>Journal of Psychiatric Research</i> , 2022 , 149, 243-251	5.2	o
21	Depression education fotonovela for engagement of Hispanic patients in treatment: a randomized clinical trial.. <i>BMC Psychiatry</i> , 2021 , 21, 635	4.2	o
20	The current crisis of confidence in antidepressants. <i>Journal of Clinical Psychiatry</i> , 2011 , 72, 27-33	4.6	o
19	Sensitivity of derived clinical biomarkers to rs-fMRI preprocessing software versions 2019 , 2019, 1581-1584	5.4	o
18	Exploring the Association of Sex Differences and Exposure to Maternal Smoking With Low Fetal Growth. <i>JAMA Psychiatry</i> , 2019 , 76, 766-767	14.5	o
17	119 Assessment of Health-Related Quality of Life and Health Status in Patients with Treatment-resistant Depression. <i>CNS Spectrums</i> , 2020 , 25, 277-278	1.8	o
16	181 A Phase-2 Sequential Parallel Comparison Design Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder. <i>CNS Spectrums</i> , 2020 , 25, 314-315	1.8	o

15	180 Improvement of Sexual Function Observed During Treatment of Major Depressive Disorder with Adjunctive Pimavanserin. <i>CNS Spectrums</i> , 2020 , 25, 313-314	1.8
14	What Did STAR*D Teach Us? Results From a Large-Scale, Practical, Clinical Trial for Patients With Depression. <i>Focus (American Psychiatric Publishing)</i> , 2012 , 10, 510-517	1.1
13	Response to Stanton, Reaburn, and Rosenbaum. <i>Journal of Psychiatric Practice</i> , 2013 , 19, 272-3	1.3
12	Which therapy for which patient? 2012 , 108-119	
11	Antecedentes familiares de suicidio consumado y características del trastorno depresivo mayor: estudio STAR*D (sequenced treatment alternatives to relieve depression). <i>Psiquiatria Biologica</i> , 2008 , 15, 195-201	0.2
10	Cognitive Therapy Versus Medication in Augmentation and Switch Strategies as Second-Step Treatments: A STAR*D Report. <i>Focus (American Psychiatric Publishing)</i> , 2008 , 6, 104-119	1.1
9	Do Dual-Action Neurotransmitter Agents Offer an Advantage in Psychiatric Treatment?. <i>CNS Spectrums</i> , 2001 , 6, 1-8	1.8
8	Do depressed patients with diabetes experience more side effects when treated with Citalopram Than their counterparts without diabetes? a STAR*D study. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , 2009 , 11, 186-96	
7	EXERCISE DOSE-RESPONSE AND CONTINUATION TREATMENT OF MAJOR DEPRESSION. <i>Medicine and Science in Sports and Exercise</i> , 2003 , 35, S216	1.2
6	Treatment-Refractory Depression. <i>Handbook of Experimental Pharmacology</i> , 2004 , 447-488	3.2
5	Pilot Studies to Evaluate Feasibility of a Physical Activity Intervention for Persons With Depression. <i>Journal of Sport and Exercise Psychology</i> , 2020 , 1-9	1.5
4	Preliminary Evidence for Sociotropy and Autonomy in Relation to Antidepressant Treatment Outcome. <i>Psychiatric Quarterly</i> , 2021 , 92, 1069-1077	4.1
3	Moderators of treatment response to exercise in participants with stimulant use disorder: Exploratory results from the Stimulant Reduction using Dosed Exercise (STRIDE) CTN-0037 study. <i>Mental Health and Physical Activity</i> , 2021 , 21, 100421	5
2	Algorithms in clinical psychiatry: a stepped approach toward the path to recovery. <i>Psychopharmacology Bulletin</i> , 2002 , 36 Suppl 2, 142-9	0.9
1	Moderation of buprenorphine therapy for cocaine dependence efficacy by variation of the Prodynorphin gene.. <i>European Journal of Clinical Pharmacology</i> , 2022 , 1	2.8